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ABSTRACT OF THESIS 
ANTIRETROVIRAL DRUG ACCESSIBILITY TO HIV/AIDS PATIENTS IN 
BAMAKO, MALI (West Africa) 
Background  
The republic of Mali is a landlocked country located in West Africa. The national HIV 
infection prevalence rate was 1.7% in 2001 and still below 2% in 2004. In Mali, ARV drugs 
are free of charge for HIV/AIDS patients. By the end of 2005 there were 6 000 HIV-infected 
patients receiving ART out of 22 000 in need (32% coverage). By 2006, it was 37% of 
coverage. Do these patients under ART have regular access to ARV? 
Objective The main objective of the study was to assess patients' perception of difficulties in 
access to ARV drugs for patients on ART 
Methods: A quantitative cross-sectional study was conducted among HIV/AIDS patients and 
dispensers at the three ARV sites in Bamako, the capital city of Mali. Data were collected 
with questionnaire by using a face-to-face interview with 210 patients under ART at least one 
month and 16 dispensers. 
Findings 
Our findings showed that ARV was perceived accessible in patients and dispensers opinions 
even though dependant variables. But some main difficulties have been cited related to the 
lack of money for transportation fee, long waiting time, stigma etc. 
138 patients (66%) were female. The mean age for patients was 35.17 ± 9.23 years. 183 
patients (87%) were residing in Bamako. 169 patients (80%) had low or no income. 
During this study, we estimated the median distance to reach the ARV site to be 9km, the 
median cost of transportation 500 Francs CFA (≈1 US dollar), the mean time to reach ARV 
site was 100.64 ± 225.80 minutes, the mean waiting time to get ARV at the treatment site 
(medical prescription plus ARV dispensing) was 3.80 ± 2.65 hours. 166 patients (79%) used 
public transportation to reach ARV sites.  
The advices given by dispensers and received by patients were not consistent. The findings 
showed existence of differences between the three ARV sites and also between genders in 
some variables. 
Conclusion: Generally, ARV was accessible to the majority of HIV/AIDS patients but some 
difficulties still existed. However another study would enable the possibility of finding out 
patients who still have no access to ARV. 
Sangho Fanta  
 IV
TABLE OF CONTENTS 
DEDICATION ............................................................................................ I 
ACKNOWLEDGEMENTS ........................................................................ II 
ABSTRACT OF THESIS ......................................................................... III 
TABLE OF CONTENTS ......................................................................... IV 
LIST OF FIGURES................................................................................ VII 
LIST OF TABLES ................................................................................. VIII 
ABBREVIATIONS .................................................................................. IX 
CHAPTER 1: INTRODUCTION ................................................................1 
1.1 Background of Mali .................................................................................... 1 
1.1.1 Main health indicators and health system .................................................................. 1 
1.1.2 Health expenditures.................................................................................................... 2 
1.1.3 National Drug Policy.................................................................................................. 2 
1.1.4 Antiretroviral (ARV) drug supply in Mali ................................................................. 5 
1.1.5 Treatment guideline in Mali....................................................................................... 7 
1.1.6 Mali’s response to the HIV epidemic......................................................................... 7 
1.2 Literature review......................................................................................... 8 
1.2.1 Antiretroviral Drugs ................................................................................................... 8 
1.2.2 Accessibility of treatment........................................................................................... 9 
1.2.3 Antiretroviral drugs accessibility to HIV/AIDS patients ........................................... 9 
1.2.3.1 Overview of the HIV/AIDS epidemic.............................................................. 9 
1.2.3.2 Condition and status of access ..................................................................... 10 
1.2.3.3 Barriers to ARV accessibility ....................................................................... 10 
1.3 Rationale of the study.............................................................................. 12 
CHAPTER 2: AIM AND OBJECTIVES ...................................................13 
2.1 Aim ............................................................................................................ 13 
2.2 Research question ................................................................................... 13 
2.3 Objective ................................................................................................... 13 
2.3.1 General objective...................................................................................................... 13 
2.3.2 Specific objectives.................................................................................................... 13 
CHAPTER 3: METHODOLOGY .............................................................14 
3.1 Materials of the present study................................................................. 14 
3.1.1 Study area................................................................................................................. 14 
3.1.2 Description of the ARV sites ................................................................................... 15 
3.1.3 Study population ...................................................................................................... 16 
3.1.4 Target population ..................................................................................................... 16 
3.1.5 Inclusion and exclusion criteria................................................................................ 16 
3.1.6 Sampling................................................................................................................... 17 
3.2 Method of the present study ................................................................... 17 
3.2.1 Study design ............................................................................................................. 17 
3.2.1.1 Benefits ......................................................................................................... 18 
3.2.1.2 Drawbacks.................................................................................................... 18 
3.2.2 Study period ............................................................................................................. 18 
 V
3.2.3 Data collection tool .................................................................................................. 18 
3.2.4 Variables................................................................................................................... 19 
3.2.4.1 Independent variables .................................................................................. 19 
3.2.4.2 Dependent variables..................................................................................... 19 
3.2.4.3 Operational definitions of variables: ........................................................... 19 
3.2.5 Recruitment and training of research assistant......................................................... 22 
3.2.6 Workshop ................................................................................................................. 22 
3.2.7 Pilot test.................................................................................................................... 22 
3.2.8 Data collection and handling.................................................................................... 23 
3.2.9 Data analysis ............................................................................................................ 24 
3.2.10 Validity and reliability ............................................................................................. 24 
3.2.11 Representativeness ................................................................................................... 25 
3.3 Ethical clearance:..................................................................................... 25 
3.3.1 Ethical approval........................................................................................................ 25 
3.3.2 Informed consent...................................................................................................... 25 
3.4 Project management:............................................................................... 25 
3.5 Dissemination of findings ....................................................................... 26 
CHAPTER 4: FINDINGS.........................................................................27 
4.1 Demographic data and respondents’ characteristics ........................... 27 
4.1.1 Patients ..................................................................................................................... 27 
4.1.2 Dispensers ................................................................................................................ 43 
4.2 Descriptive Statistics for some variables .............................................. 44 
4.3 Advices during ARV dispensing............................................................. 45 
4.4 Univariate descriptive statistics.............................................................. 46 
4.5 Dependant variables ................................................................................ 47 
4.5.1 Geographical accessibility........................................................................................ 47 
4.5.1.1 Geographical accessibility by distance covered to reach ARV site ............. 47 
4.5.1.2 Geographical accessibility by time spent to reach ARV site........................ 48 
4.5.2 Financial accessibility .............................................................................................. 48 
4.5.3 Opinion of informants about accessibility of ARV.................................................. 49 
4.5.4 Quality of dispensing ............................................................................................... 49 
4.5.5 Patient’s satisfaction with dispensing manner ......................................................... 50 
4.5.6 Staff coverage for dispensing................................................................................... 50 
4.6 Analytical findings ................................................................................... 51 
4.7 Gender analysis........................................................................................ 57 
CHAPTER 5: DISCUSSION ...................................................................61 
5.1 Strengths of the study: ............................................................................ 61 
5.2 Limitations ................................................................................................ 61 
5.3 Discussion of findings............................................................................. 62 
5.3.1 Characteristics of the respondents............................................................................ 62 
5.3.2 Difficulties experienced ........................................................................................... 63 
5.3.3 Opinions of patients ................................................................................................. 65 
5.3.4 Dispensing manner................................................................................................... 66 
5.3.5 Descriptive statistics by site ..................................................................................... 67 
5.3.6 Dependant variables ................................................................................................. 67 
5.3.7 Disclosure challenge ................................................................................................ 69 
5.3.8 Gender analysis ........................................................................................................ 70 
CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS.................71 
 VI
6.1 CONCLUSIONS......................................................................................... 71 
6.2 RECOMMENDATIONS.............................................................................. 72 
REFERENCES.......................................................................................74 
LIST OF ANNEXES................................................................................78 
Annex 1:  Questionnaire for patients............................................................... 78 
Annex 2:  Questionnaire for dispensers ......................................................... 83 
Annex 3:  Questionnaire for patients (in French) ........................................... 85 
Annex 4:  Questionnaire for dispensers (in French) ...................................... 91 
Annex 5:  Consent form for patients (in French)............................................ 93 
Annex 6:  Consent form for dispensers (in French)....................................... 95 
Annex 7:  Ethical approval from Norway......................................................... 97 
Annex 8:  Ethical approval from Mali............................................................... 98 
 
 VII
LIST OF FIGURES 
Figure 1: Procurement scheme in Mali ...................................................................................... 4 
Figure 2: ARV supply scheme in Mali....................................................................................... 5 
Figure 3: Map of Bamako District with the three ARV sites................................................... 14 
Figure 4: Gender of patients..................................................................................................... 27 
Figure 5: Patients according to age group................................................................................ 28 
Figure 6: Profession of the patients under ARV treatment ...................................................... 29 
Figure 7: Residence of the HIV/AIDS patients........................................................................ 30 
Figure 8: Distribution of the patients according to the income level ....................................... 31 
Figure 9: Duration of ARV treatment by year ......................................................................... 32 
Figure 10: Distance to the ARV site according to patient opinion .......................................... 33 
Figure 11: Time spent to reach the ARV site........................................................................... 33 
Figure 12: Opinion on the time spent to get ARV in the treatment site................................... 34 
Figure 13: Time spent to get ARV drugs in hours ................................................................... 34 
Figure 14: Time spent to get medical prescription in hours..................................................... 35 
Figure 15: Waiting time at the treatment sites in hours ........................................................... 36 
Figure 16: Possession of means of transportation.................................................................... 36 
Figure 17: Money spent on food by patients............................................................................ 38 
Figure 18: Opinion about difficulties ....................................................................................... 38 
Figure 19: Opinion about the level of ARV accessibility ........................................................ 40 
Figure 20: Receiving ARVs in presence of other people......................................................... 42 
Figure 21: Opinion about the presence of other people during the dispensing........................ 42 
Figure 22: Comparison of advices as reported by patients and dispensers .............................. 45 
Figure 23: Geographical accessibility by distance covered to reach ARV site ....................... 47 
Figure 24: Geographical accessibility by time spent ............................................................... 48 
Figure 25: Opinion of the patients about dispensing manner................................................... 50 
Figure 26: Marital status according to gender.......................................................................... 57 
Figure 27: Comparison of patients’ income by gender ............................................................ 59 
 
 VIII
LIST OF TABLES 
Table 1: Patients under ARV by July 2006 and sample size ................................................... 17 
Table 2: Distribution of patients between the sites .................................................................. 27 
Table 3: Patients according to the marital status...................................................................... 28 
Table 4: Distribution of patients between the 6 communes of Bamako .................................. 30 
Table 5: Distribution of the means of transportation ............................................................... 37 
Table 6: Difficulties mentioned by patients ............................................................................. 39 
Table 7: Opinion about accessibility of ARV drugs ................................................................ 40 
Table 8: Suggestions for better access for ARV by patients.................................................... 41 
Table 9: Distribution of the 16 dispensers between the ARV sites.......................................... 43 
Table 10: Descriptive statistics for patients attending all three ARV sites .............................. 44 
Table 11: Estimated means test by ARV site........................................................................... 46 
Table 12:  Financial accessibility of ARV by patients............................................................. 48 
Table 13: Quality of dispensing ............................................................................................... 49 
Table 14: Geographical accessibility by distance covered for each dispensing site ................ 51 
Table 15: Geographical accessibility by time spent for each dispensing site .......................... 52 
Table 16: Financial accessibility for each dispensing site ....................................................... 52 
Table 17: The opinion of the patients on the dispensing manner for each ARV site............... 53 
Table 18: Opinion on the time spent to get ARV for each ARV site....................................... 53 
Table 19: Means of transportation by ARV site ...................................................................... 54 
Table 20: Association between the means of transportation and having an income................ 55 
Table 21: Income and transportation fee.................................................................................. 56 
Table 22: Means of transportation according to gender........................................................... 58 
 
 IX
ABBREVIATIONS 
AIDS  Acquired Immunodeficiency Syndrome  
ART  Antiretroviral Therapy  
ARV  Antiretroviral 
CESAC Center for listening and counselling for HIV-infected patients  
CHC  Community Health Centers,  
DPM  Direction of Pharmacy and Medicines  
EDS III Health and Demographic Survey  
ESTHER Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau 
FMPOS Faculty of Medicine Pharmacy and Odonto-Stomatology 
GDP  Gross Domestic Product  
HAART Highly Active Antiretroviral Therapy  
HCNLS National High Council for AIDS control  
HGT  Hospital Gabriel Touré  
HIV  Human Immunodeficiency Virus  
HIV/AIDS Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome  
HPG  Hospital of Point G  
IDU  Injecting Drug Users  
IMAARV Malian Antiretroviral Drug Access Initiative  
INN  International Non-proprietary Name  
Km  Kilometer  
Min  Minute  
MoH  Ministry of Health  
NDP  National Drug Policy  
NEDL  National Essential Drugs List  
NGO  Non Governmental Organisation  
NLQ  National Laboratory of Quality  
NNRTI Non-Nucleoside Reverse Transcriptase Inhibitors  
NOK  Norwegian currency  
NRTI  Nucleoside/Nucleotide Reverse Transcriptase Inhibitors  
PI  Protease Inhibitors  
PLWHA People living with HIV/AIDS  
PMTCT Prevention of Mother to Child Transmission  
PPM  Government central medical depot  
SOLTHIS Solidarité Thérapeutique et Initiatives contre le SIDA 
SSA  Sub-Sahara Africa  
TB  Tuberculosis  
UNAIDS United Nations Joint Programme on AIDS  
UNICEF United Nations Children’s Fund  
WHO  World Health Organisation 
 
 1
CHAPTER 1: INTRODUCTION 
1.1 Background of Mali 
The Republic of Mali is a landlocked country located in West Africa with an area of about 
1,241,000 km2 and 13.518 million inhabitants (1). The capital city is Bamako. The country is 
divided into eight administrative regions namely Kayes, Koulikoro, Sikasso, Ségou, Mopti, 
Toumbouctou, Gao and Kidal. People are divided into many different ethnic and linguistic 
groups. Mali being a former French colony has French as official language. However, around 
80% of the population speak Bambara (language of Bambara ethnic group). 
1.1.1 Main health indicators and health system   
• The life expectancy  at birth was 48.3 years in 2004 
• The child mortality rate under 5 years was 21.9% in 2004 (2) 
• The adult mortality rate 15-60 years old was 47.5% for female and 40.9% for male (1)  
• The national Human Immunodeficiency Virus (HIV) infection prevalence rate was 
1.7% in 2001 (3) and still below 2% in 2004 (4). 
The health sector policy is based on community self-financing (user fee and cost-recovery).  
The health system is organized into public and private sectors. The public sector is organized 
into four levels which are: 
• The first level is made of the Community Health Centers (CHC) that is in French  
Centre de Santé Communautaire (CSCOM) 674 by June 2004 (5) and 729 by June 
2005 (6) 
• The second level corresponds to the first referral made of the District Health Centers 
(DHC). There were about 58 DHC as at June 2004 (5) 
• The third level is made of regional hospitals in each of the 8 regions of Mali 
• The fourth level national hospitals  
 
In Mali, there are many health institutions and nursing schools where health workers are 
trained such as the Faculty of Medicine Pharmacy and Odonto-Stomatology (FMPOS) -
Faculté de Médecine, de Pharmacie et d’Odonto-Stomatologie. In addition, Mali has a 
national laboratory for drug, food and water quality control - National Laboratory of Quality 
(NLQ) or Laboratoire National de la Santé: LNS. 
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There are also various disease control programs which target: Malaria, Human 
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), Tuberculosis 
(TB), Shistosomiasis etc.  
 
With the creation of the National High Council for AIDS control (HCNLS in French Haut 
Conseil National de Lutte contre le SIDA), the program of HIV/AIDS was dissolved and 
replaced by a unit called Cellule Sectorielle de Lutte contre le SIDA under the responsibility 
of the Ministry of Health (MoH).  
1.1.2 Health expenditures 
Mali is one of the poorest countries in the world, with a Gross Domestic Product (GDP) of  
1 000 US dollars. The health expenditure approximated 6.6% of the GDP in 2004. The total 
health expenditure per capita was 54  US dollars in 2004 (1).  
1.1.3 National Drug Policy 
The National Drug Policy (NDP) or Politique Pharmaceutique Nationale (PPN) was adopted 
in June 1998. The main goal of the pharmaceutical policy is to make good quality essential 
drugs accessible geographically, physically and financially to the population (7). 
The drug policy is also based on the concept of essential drugs with emphasis on promotion of 
generic drugs under International Non-proprietary Name (INN) -Denomination Commune 
Internationale (DCI). (8). 
The NDP is based on essential drugs selected through the National Essential Drugs List 
(NEDL) -Liste Nationale des Médicaments Essentiels (LNME) which is revised every two 
years. The last known revision took place in February 2006. 
It is necessary to indicate that essential medicines are those that satisfy the priority health care 
needs of the population (9) 
 
In 1995, after the devaluation of Francs CFA (local currency in Mali), there was a health 
initiative under the Implementation of Procurement and Distribution Scheme (IPDS) -Schema 
Directeur d’Approvisionnement et de Distribution des Médicaments Essentials (SDADME). 
Under the scheme, all public health facilities received the first stock of medicines based on 
costs at unit level: regional hospital, district warehouse or drug outlet. Appropriate cost – 
recovery plan was required to permit and maintain regular supply. Funds collected from the 
drugs sold at health services are used to buy and replenish sold drugs.   
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In the process, it was observed that collaboration between public and private sector would 
improve availability of drugs. 
 The Direction of Pharmacy and Medicines (DPM) - Direction de la Pharmacie et du 
Médicament (DPM) established in September 2000 is responsible for coordination of 
different activities in the pharmaceutical sector. 
The supply pipeline in Mali is 12 months (from central level to drug outlet). 
Procurement of essential drugs for the public sector is done by the government’s central 
medical depot, Pharmacie Populaire du Mali (PPM). Drugs are bought through competitive 
tenders and based on established annual procurement scheme. Most of the tender processes 
are done under INN. However, the main source of drug supply for all public health facilities is 
the PPM. In the case of shortage at PPM or/and regional warehouse public, health units can 
order drugs from the private wholesalers and their regional unit.    
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Figure 1: Procurement scheme in Mali 
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1.1.4 Antiretroviral (ARV) drug supply in Mali 
 
 
At the time of data collection ARVs were only available through public sector, at national and 
regional levels. 
The technical services involved in the management of ARV drugs are: 
• HCNLS which coordinates all activities in the fight against HIV/AIDS in Mali. 
• The financial service of the Ministry of Health, Direction Administrative et Financier 
(DAF), is responsible for buying the ARV drugs. 
• The DPM is in charge of drug order processing for the Ministry of Health.  
• The PPM is specifically responsible for ARV procurements: order, storage and 
distribution, to the treatment sites (ARV sites) based on regular scheme.   
• ARV sites: the sites managers are pharmacists who estimate the needs of drugs based 
on the number of patients and treatment regimes (treatment type). They do the 
dispensing and also give advices to patients. 
In addition to the above structures, there are two other committees involved in the ARVs 
program: a therapeutic committee which is responsible for the choice of the treatment regimes 
(first and second lines) and another committee - Committee for ARV Drugs and Lab Tests 
Management, which is responsible for monitoring of the ARV drugs.   
It is to be noted that Mali does not produce ARV drugs; therefore, procurement of ARV drugs 
is based on importation.  
Figure 2: ARV supply scheme in Mali 
Regional sites Bamako 
PPM 
Suppliers 
ARV drugs supply Chart 
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1. Quantification of ARV drugs 
Each treatment site makes an expression of needs or requisition for ARV drugs to cover one 
year. The quantification of needs is done by the pharmacist and the prescriber (skilled medical 
doctor) based on: 
• Treatment guidelines (protocols) 
• Monthly inclusion of new AIDS patients 
• Last drugs consummation (monthly or annually)  
The DPM thereafter compiles various decentralized quantifications from each treatment site. 
The general requisition or needs of ARV drugs is transmitted to the financial service of the 
MoH which commands PPM of ordering the drugs. 
 
2. Financing 
The purchase of ARV drugs is dependent on funds availability. For example in 2004, only 1/3 
of the drugs needed were bought by the PPM. But, nowadays the supply is becoming regular.  
The main fundings are from the national budget, Global Fund, World Bank, United Nations 
Children’s Fund (UNICEF), Ensemble pour une Solidarité Thérapeutique Hospitalière en 
Réseau (ESTHER), Solidarité Thérapeutique et Initiatives contre le SIDA (SOLTHIS) etc. 
The latter organisations, ESTHER and SOLTHIS, are French Non Governmental 
Organisation (NGO). 
 
3. Procurement 
In Mali, drugs for AIDS are supplied by the PPM.  
After the needs are estimated by the sites, an extra quantity of drugs that accounts for about  
3 - 4 months supply is added to the general order. At the moment, the private sector is not 
enrolled in the ARV drugs procurement and distribution. 
Upon reception at central level, the stock is placed under quarantine for laboratory test 
(quality control). In Mali, however the NLQ is not well equipped to performing all the 
necessary tests for drug quality control.   
 
4. Distribution 
ARV drugs are initially stored by PPM and gradually distributed according to the needs of the 
different treatment sites based on their monthly request. These ARV drugs are distributed 
based on drugs availability at central storage. 
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In many instances, a treatment site can utilize its means of transportation in collection of 
supplies or allocated drugs so as to avoid long distribution delay which could lead to shortage. 
In a case of shortfall in distributed supplies, a treatment site is permitted to make a return 
journey to collect outstanding allocations whenever it is available.   
 
5. Dispensing 
The ARV sites are the only structures approved for dispensing drugs to patients. The 
dispensing is done under the responsibility of pharmacists who are also the site managers. 
1.1.5 Treatment guideline in Mali   
The treatment is mostly based on: 
•  2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI) + 1 Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTI) which are expected to cover 
80% of the needs of new patients  
• 2 NRTI + 1 Protease Inhibitors (PI) 
First line treatment  
Stavudine (D4T) + Lamivudine (3TC) + Nevirapine (NVP)  
Alternative regimes 
Zidovudine (ZDV) + Lamivudine (3TC) + Efavirenz (EFZ) 
Zidovudine (ZDV) + Lamivudine (3TC) + Nevirapine (NVP) 
Stavudine (D4T) + Lamivudine (3TC) + Efavirenz (EFZ)  
Particular case of TB 
Stavudine (D4T) + Lamivudine (3TC) + Efavirenz (EFZ)  
 
Second line treatment  
Abacavir (ABC) + Didanosine GR* (DDI) + Indinavir/Ritonavir (IDV/r) 
*GR = gastro-resistant 
All theses ARV drugs except Ritonavir can be store at room temperature, which is 15 – 25 
degrees Centigrade, up to 30 in some climatic zones.  
1.1.6 Mali’s response to the HIV epidemic 
The Malian Antiretroviral Drug Access Initiative - Initiative Malienne d’Accès aux 
Antiretroviraux (IMAARV) was launched in 2001.  
During this period, ARV drugs were subsidized and only available at the three treatment sites, 
all located in Bamako: 
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• Two national hospitals: Hospital Gabriel Touré (HGT) and Hospital of Point G (HPG)  
• One NGO: Center for Listening and Counselling for HIV-infected patients - Centre 
d’Ecoute, de Soins, d’Animation et de Conseil (CESAC)  
 
It was not until 2005, that the government of Mali declared ARV drugs free of charge for 
every patient in need under Decree No 05 – 147/P-RM of 31/3/2005. The free ARV drugs 
were facilitated by the Global Fund and partners such as ESTHER (Bamako, Kayes and 
Sikasso), SOLTHIS (Ségou) and the creation of the High Council for AIDS Control for Funds 
Mobilisation. 
 
From being subsidized in 2001, ARV drugs were made free of charge in 2005 for every AIDS 
patient in need. The ARV prescriber’s guideline was that a beneficiary tests HIV positive and 
also meet biological criteria stipulated under the overall national guideline.  In April 2006, 
there were 14 ARV sites and 60 Prevention of Mother to Child Transmission (PMTCT):  
Prevention de la Transmission Mère-Enfant (PTME) sites in Mali. 
In addition to the existing centers, there are related projects. The treatment is based on tri-
therapy and is delivered through 14 ARV sites, all located in urban centers.  
Free ARV drugs encourage people to undergo screening for their HIV status because of the 
treatment opportunity and availability. A good antiretroviral therapy (ART) requires an 
efficient ARV drug procurement scheme and a regular availability. However, making drug 
available at ARV sites through a well organized procurement scheme does not necessary 
make drug accessible to HIV/AIDS patients. Therefore accessibility to ARV drugs is a 
crucial component for the success of ART. 
1.2 Literature review 
1.2.1 Antiretroviral Drugs 
ARV inhibits the replication of HIV. There are four main groups of anti-HIV drugs. Each of 
these groups attacks HIV in different ways. 
• NRTI 
• NNRTI 
• PI 
• Fusion or Entry Inhibitors (10).  
Of these 4 groups of drugs, only the fusion inhibitors are not used in Mali.  
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ART is the main type of treatment for HIV/AIDS. Though it is not a cure, but it can prevent 
people from becoming ill for many years. Thus ART seeks to improve HIV patients’ quality 
of life. 
The term Highly Active Antiretroviral Therapy (HAART) is used to describe a combination 
of three or more anti-HIV drugs. The treatment consists of drugs that have to be taken every 
day for the rest of the patient's life (11) 
Access to antiretroviral therapy is essential for survival of people living with HIV/AIDS (12). 
1.2.2 Accessibility of treatment 
Access to drugs depends on four key points: rational selection, affordable prices, sustainable 
finances and reliable health systems. A barrier to access to treatment is anything that prevents 
patients from getting the treatment they need (13). 
There are different types of barriers to access to HIV/AIDS-related treatment: 
• Financial barriers – such as the cost of drugs and the need to prioritize other general 
supplies, such as food; 
• Organizational barriers – such as poor administration of treatment services and lack of 
skilled staff; 
• Physical barriers – such as treatment facilities being distant and transport not being 
available; and 
• Social barriers – such as stigma being associated with a HIV treatment and patients 
concern on issues of confidentiality. 
Access may also be measured by distance, time, costs, or social and cultural factors (14).   
1.2.3 Antiretroviral drugs accessibility to HIV/AIDS patients 
1.2.3.1 Overview of the HIV/AIDS epidemic 
AIDS was first recognized in 1981, and since then more than 25 million people have died 
from it. AIDS is the leading cause of death worldwide, closely followed by TB and malaria 
(15).  
In 2005, 40.3 million adults and children were living with HIV. Among those, 25.8 million 
lived in Sub-Sahara Africa (SSA). More than 77% of the 3.1 millions annual deaths due to 
AIDS occur in SSA countries (4). 
HIV spreads through high risk groups such as men who have sex with men and Intravenous 
Drug Users (IDU) in developed countries.  
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For the developing countries, it is usually through heterosexual contact, transmission from 
mother to child during pregnancy and delivery, and contaminated blood in medical area (15). 
1.2.3.2 Condition and status of access 
Despite the burden caused by the AIDS epidemic, access to ART is till very low.  
In June 2005 for example, only 1 million received ART (15% coverage) out of 6.5 million  
(0-49 years old) who were in need in low and middle-income countries under “3 by 5” 
initiative (means treated 3 million patients in need at the end of 2005) (4).   
According to the report of  the World Health Organisation (WHO) and the United Nations 
Joint Programme on AIDS (UNAIDS),  1.3 million people were receiving treatment at the end 
of December 2005 (16).  
In Mali, 6 000 HIV-infected patients received ART in December 2005 out of 22 000 (0-49 
years old) in need (32% coverage). The average monthly inclusion is 349 patients which 
represents those eligible for treatment (medical criteria) (16). The recent report from April 
2007 indicated a ART coverage of 37% (17).   
1.2.3.3 Barriers to ARV accessibility 
1) Cost of ARV 
Cost of ARV drugs is observed to be one of the most important barriers that contribute to its 
inaccessibility. 
a) ARV not free  
In Burkina-Faso, Nguyen et al. (2003) demonstrated that the cost of drugs has been and 
remains the main barrier to increased access and adherence to treatment. 
In Botswana, Weiser et al. (2003) established that the cost was the most significant treatment 
barrier to ART adherence. 
In Malawi, van Ooterhout et al. (2005) stated that the most important reasons for non-
adherence were shortage of drugs in the hospital pharmacy and personal financial constraints.  
In Rwanda, Fisher et al. (2006) found that 24% of patients who interrupted treatment have 
done so because of financial problems. 
The conclusion of these four studies is that ARV should be either subsidized or made free of 
charge to patients in order to increase treatment access (18-21). 
b) ARV subsidization: Taverne’s study 2003 showed that subsidizing ART is not enough to 
favour better access as shown by the experience of some countries (Ivory Cost, Senegal, and 
Mali) (22).  
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In Ivory Cost, while the awareness about existing drug program limited access to ART (23), 
the fee paid by the patient also represents major obstacle for proper medical management. 
Therefore, free access should be implemented in Africa countries (22).  
It is expected that free access should provide rational treatment to patients and reduce the 
demand for ARV drug on the informal market that can reduce the risk of resistance due to 
misuse or inappropriate use. (24).  
 
2)  Free access to ARV 
The question may arise as to the accessibility level to ARV drugs after the removal of cost for 
HIV/AIDS patients. Theoretically, free access should necessarily improve accessibility to 
ARV drugs. But in practice, certain barriers may still exist. 
a) Demographic characteristics: age and sex  
A study carried out in British Columbia, Canada among IDU showed that ART drugs were 
accessible for female and young people. Female IDU are twice less likely to receive ART 
than male. Young IDUs were however less aware of ART benefits, and less likely to seek care 
(25). The investigators did not explore barriers for female to access ART and the IDUs 
constitute a specific group of patients. 
b) Time and cost of transport 
The limitation of ARV access was shown to be related to cost of transportation by Benjaber et 
al. From a study on antiretroviral treatment compliance carried out in Morocco there was 
considerable distance between patient settlements and treatment sites. (26).  
c) Difficulty in picking up medication 
An evaluation of ART in a Rio de Janeiro public clinic showed that 23.7% (14/59) of AIDS 
patients lacked medication for more than a month. Among those 78% did not manage to pick 
up their medication but the investigators did not report the reason which could include stigma, 
waiting time etc. (27). 
d) Lack of adequate health care delivery system 
The issue of confidentiality is crucially important in view of widespread AIDS related stigma 
and discrimination (28). In Mali, the lack of adequate facilities for dispensing presents serious 
challenge to protect patients’ confidentiality. In this case, some patients would prefer to get 
their medication outside the working days, usually on Saturdays (29).  
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1.3 Rationale of the study 
The problems related to ARV drugs accessibility for HIV/AIDS patients are of geographical, 
economical and socio-cultural type. An irregular access to antiretroviral drugs could lead to 
drug resistance and increased morbidity and mortality of these patients (18;26;27;30). 
HIV/AIDS patients are subject to stigma and discrimination. However,  HAART transforms 
AIDS from a debilitating and fatal disease to a chronic and manageable one (31). 
Investigators from Uganda concluded that stigma could be reduced if ARV drugs are 
integrated in the general drug supply scheme (32).  
Some settings are not accessible during rainy season (33) which could disturb drug 
availability and accessibility. When patients do not pick up their medication, the drugs could 
expire, causing wastage of the scare resources in poor setting. 
 From the light of these studies, one could say that accessibility to ARV is a prerequisite for 
treatment use, compliance or adherence. ARV drugs for a treatment can be available locally 
but at the same time are not accessible (13). Few studies were done for ARV drugs 
accessibility. However, to our knowledge no study has explored ARV drugs accessibility 
in a poor, non-ARV drug-producing setting, where these drugs are made free.  
In Mali, ART program is going to be expanded, the present study will explore the difficulties 
that ART patients encounter when getting their ARV drugs in order to make efficient, the 
expansion of ARV sites. 
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CHAPTER 2:  AIM AND OBJECTIVES 
2.1 Aim 
Numerous barriers can limit access of HIV/AIDS patient to ARV drugs: location of ARV 
dispensing sites, cost of transportation, long waiting time, stigma and discrimination, trust in 
health system and ARV drugs, insufficiency of qualified personnel for dispensing, manner of 
ARV dispensing etc. 
Our study will focus on geographical and financial accessibility, quality of dispensing and 
opinions of HIV/AIDS patients and dispensers, on ARV drugs accessibility. 
In the light of these public health major challenges, this study is undertaken with a view to 
provide some recommendations that will improve and facilitate ARV access to HIV/AIDS 
patients.   
The findings will identify and illustrate difficulties to ARV drugs accessibility which can be 
related to patient and/or to a country’s health system.  
2.2 Research question 
What are the difficulties which limit ARV drug accessibility for HIV/AIDS patient? 
2.3 Objective 
2.3.1 General objective 
To identify and assess difficulties to ARV drugs accessibility for HIV/AIDS patients 
2.3.2 Specific objectives 
1. To describe the socio-demographic variables (sex, age, profession, income etc) 
2. To determine the average distance for patient to reach treatment site 
3. To determine the mean time spent by patients, to reach ARV sites 
4. To determine the mean waiting time to get ARV drugs 
5. To determine the means and cost of transportation 
6. To identify other problems associated with access to ARV drugs  
7. To determine the quality of dispensing in terms of confidentiality and advices 
8. To describe patient and dispenser’s opinion on ARV drugs accessibility 
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CHAPTER 3: METHODOLOGY 
3.1 Materials of the present study 
3.1.1 Study area 
 
Figure 3: Map of Bamako District with the three ARV sites 
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The study was conducted in three ARV sites which were providing ART in Bamako, the 
capital city of Mali. Bamako is situated on the Niger River, in south-west of Mali. In 2006, 
Bamako’s population was 1 690 471. (34). Bamako is divided into 6 communes or 
municipalities (commune I, II, III, IV, V and VI) and 60 areas (“quartiers”). In December 
2004, Bamako had: 50 Community Health Centers based on community responsibility and 6 
district clinics. Each commune has a health center under Bamako’s two national hospitals. 
Two out of Mali’s three national hospitals are located in Bamako. These are: HGT and HPG 
both with status of University Hospitals - Centre Hospitalo-Universitaire (CHU). The third is 
a national hospital for mother and child hospital - Hôpital Mère-Enfant called “Luxembourg”  
The choice of Bamako is justified by the fact that it was not only the first ARV sites in Mali 
but retains the experience since 2001. At that time, ARV drugs were subsidized through the 
Malian Antiretroviral Drug Access Initiative launched in 2001. The three treatment sites 
which cover approximately 80% of HIV/AIDS patients in Mali (29) are all located in Bamako 
as follows:  
• HGT 
• CESAC 
• HPG 
Each of the three sites has it own organisations of People living with HIV/AIDS (PLWHA) 
such as: 
• ”Sabougnouma” at HGT 
• AMAS/AFAS  at CESAC 
• ”Yeléen” at HPG 
These organisations help a lot in HIV/AIDS patients’ support. 
The district of Bamako, with 2.5%, had the highest rate of HIV prevalence inside the country 
followed by the regions of Kayes, Ségou and Koulikoro 1.9% each (3). 
In May 2005, 3102 HIV-infected patients received ART in Bamako. The repartition were 750 
at HGT, 1445 patients at CESAC and 907 patients for HPG (29). However in July 2006, it 
was 6343 patients, over the double under ART, 1299 patients at HGT, 3199 at CESAC and 
1845 at HPG from which the samples for this study were drawn. 
3.1.2 Description of the ARV sites  
1) HGT 
Hospital Gabriel Touré is the only site which dispenses ARV to the children. The consultation 
is done in the paediatric unit.  
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The consultation for adult is done in the unit of gastro-enterology. The site had around 75 
patients (adult and children) per day. HGT is located in the second commune of Bamako. 
2) CESAC 
CESAC is located in Commune III of Bamako. This site is closely situated to the big market 
of Bamako (Grand marché de Bamako). CESAC specialises on HIV/AIDS treatment. The site 
receives around 113 patients per day. 
3) HPG 
Like CESAC, HPG is also located in the third commune in Bamako but on the hill side. The 
consultation is done at the infectious diseases unit. The dispensing is done for 38 patients per 
day. 
3.1.3 Study population 
The specific population from which data are collected is called the study population (35). 
The study population consisted of patients under ART (18 – 65 years old) who frequented the 
three ARV sites in the study period and the dispensers in these sites. The informant was 
recruited in the ARV sites and interviewed. 
3.1.4 Target population 
The population from which conclusions are drawn is called the target population (35). The 
target group for our investigation was HIV/AIDS patients under antiretroviral therapy in the 
three ARV sites in Bamako and all dispensers. 
3.1.5 Inclusion and exclusion criteria 
All dispensers in the three sites were included in our study. The criteria for HIV/AIDS 
patients were the following:  
Inclusion criteria: our study included every patient aged 18 to 65 that has been under ART 
for at least one month. The age group 18 years and above were selected because it consists of 
people assumed to be responsible for getting their own ARV drugs and they can support their 
own views. 
Exclusion criteria: The following informants were excluded:  
• Pregnant women 
• Patients below 18 years old 
• Patients above 65 years old 
• Hospitalized patients  
• Informant not willing to participate. 
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3.1.6 Sampling   
The sample procedure was a non-probability sampling (convenience sampling). Convenience 
sampling was chosen because of some characteristics of our study for example: many 
dependent variables, scare data on accessibility and limited resources (time and funds). 
The sample selection should have been randomly, being an ideal method for survey (36). In 
practice however, it was shown that drawing patients from the list of ARV site is extremely 
difficult especially in effort to interview all of them, because of their lack of regularity at 
ARV sites during the data collection period.  In many of such instances, lack of complete 
addresses and/or the lack of disclosure about medical condition to their family members 
or/and community reduced possibility of follow-ups or monitoring. 
In all, our sample was 210 HIV/AIDS patients and 16 dispensers located around the three 
ARV sites. The repartition was done according to the number of patients per site. 
Table 1: Patients under ARV by July 2006 and sample size  
ARV site Number of patients HIV/AIDS Study sample 
HGT 
 
1 299 43 
CESAC 
 
3 199 106 
HPG 
 
1 845 61 
Total 
 
6 343 210 
 
Every patient willing to participate after receiving their drugs (who meets our inclusion 
criteria) was interviewed. All dispensers in the three sites were interviewed. The informed 
consent of the informant was sought and obtained. We stayed at the ARV sites until the 
securing of required number of informants needed for inclusion in the study.  
3.2 Method of the present study  
3.2.1 Study design 
A quantitative study using a cross sectional design was used to assess difficulties to free 
access to ARV drugs by HIV/AIDS patients in Bamako, Republic of Mali. 
Many cross-sectional studies are descriptive, and these are called surveys. All information is 
collected at the same time because subjects are only contacted once (36). 
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3.2.1.1 Benefits 
A cross-sectional study is most useful for description (35;37). Descriptive study involves the 
description of characteristics of a particular situation, event or case (37). In this circumstance, 
cross-sectional survey is a suitable design, when little is known of the phenomenon under 
investigation.  
Our study intends to provide the baseline data which can help policy-makers to improve 
ARV drugs accessibility to HIV/AIDS patients. 
Cross-sectional study does not suffer from many disadvantages such as recall bias and loss 
due to follow-ups as it is usually the case in cohort study. In addition, cross-sectional study is 
relatively cheap and easy to carry out (36). 
3.2.1.2 Drawbacks 
• Sample selection 
The weakness of most observational studies is that the sample may not be representative of 
the population investigated. The validity of the extrapolation is therefore crucially dependent 
on the representativeness of the sample 
• Response rate 
By using postal questionnaire, the response rate could be low (36).  
However in our case a face-to-face interview provided a high response rate. The information 
was collected at the same time as the informant was contacted. The questionnaire was usually 
more completely filled than self-administered questionnaire for example. Finally, the cultural 
context in Mali and the level of illiteracy favoured face-to-face interviews.  
The questionnaire assured the confidentiality of the information which is very important in 
HIV area.  
3.2.2 Study period 
The fieldwork was conducted in five months, from July to November 2006. 
3.2.3 Data collection tool 
The research tool (questionnaire) contained both close-ended and open-ended questions.  
The closed-ended questions concerned the independent variables while the open-ended 
questions covered the dependant variables concerning views of informants.  
Open-ended question was asked about the opinion of patients and dispensers on ARV drugs 
accessibility and also patient’s satisfaction with manner of drug dispensing. 
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The questionnaire was constructed in English and translated into French because Mali is a 
French-speaking country. After the workshop, some improvements were made to the 
questionnaire.  
3.2.4 Variables 
The following variables were included in our study: 
3.2.4.1 Independent variables 
• The socio- economic variables were as follows: sex, age, level of schooling, marital 
status, profession, patient’s income and residence. 
• The difficulties variables were the distance covered by patient, the time spent to reach 
treatment site, the time spent to get ARV drugs, the time spent to get prescription, the 
means of transportation and the cost of transportation. 
3.2.4.2 Dependent variables 
-   The geographical accessibility was estimated by the distance covered and the time spent 
-   Financial accessibility 
-   Opinion of informants about accessibility 
-   Quality of dispensing  
-   Patient’s satisfaction with dispensing  
-   Staff coverage for dispensing 
3.2.4.3 Operational definitions of variables:  
The definitions used in our study were: 
Difficulty: anything that can limit an HIV/AIDS patient on antiretroviral therapy to get 
regular access to antiretroviral drugs. 
Dispenser: any person (pharmacist or other personal) who dispenses ARV drugs. 
Gender and age 
• Gender  was Female or Male  
• Age the age was recorded in years 
Gender and age can influence ARV drugs access according to the literature (25).  
Level of schooling means the numbers of years in formal schooling. The level of schooling 
was categorised as follows: 
• No schooling (0 year) 
• Primary school (1 – 6 years)  
• Junior high school (7 – 9 years)  
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• Secondary school (10 – 12 years)  
• Higher education (>12 years) 
The educational background could contribute to increased access to ARV. 
Marital status was categorised as single, married, widowed and divorced  
In Malian context, marital status could influence financial support for transportation costs. A 
married woman for example is more likely to get support from her husband. 
Profession of the patient was relevant and asked because his/her profession could guide us 
about his/her income. 
Income of patient means how much the patient earns per month. The income provided an 
insight whether or not the patient could afford to pay the transportation costs. The 
categorisation of the income level was as fellows: no income = 0 Franc CFA, low income 
from 7 000 to 50 000 Francs CFA, moderate income from 50 005 to 100 000 Francs CFA and 
high income above 100 000 Francs CFA. 
Residence: the residence of patient was reported. The report enabled an estimation of distance 
covered by patient if the patient was not able to give us this figure. 
Distance covered by patient means the distance to reach the treatment site. 
Time spent to reach treatment site means the time spent by patient to reach the ARV site. 
Time spent to get ARV drug means the time spent by patient at the ARV site before 
receiving ARV drugs. 
Time spent to get medical prescription means the time spent by patient at the treatment site 
before receiving medical prescription. 
Waiting time means the time spent at the treatment site to get medical prescription and ARV 
drugs. 
Means of transportation is the type of transportation used by the patient to reach the 
treatment site. They were categorized as foot, bus, taxi, train, car, bike, motorbike and others. 
Cost of transportation: money spent by patient to reach treatment site.  
Geographical accessibility: the geographical accessibility was defined according to distance 
covered or the time spent by the patient to reach the ARV site. We had two sub-variables 
which were: accessibility by distance and the accessibility by time.  
Categorization was done according to the distance or the time as follows:  
1) Accessibility by distance covered.  
The following categorization was used in terms of distance covered by HIV/AIDS patients: 
• Very accessible, if the distance covered was ≤ 5 kilometers (km)   
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• Accessible, if the distance was >5 - ≤ 15km  
• Less accessible, if the distance covered was > 15 - ≤ 30km  
• Not accessible, if the distance covered was > 30km   
2) Accessibility by time spent: 
The following categorization was used in terms of time spent by HIV/AIDS patients: 
• Very accessible, if the time spent was ≤ 30 minutes (min)   
• Accessible, if the time spent was 31- 60 min  
• Less accessible, if the time spent was 61- 180 min   
• Not accessible, if the time spent was > 180 min   
Financial accessibility: this represents the cost of transportation in percentage of patient 
income. The financial accessibility was categorised as follows:  
• Very accessible, if the cost of transportation represented less than 5% of the 
patient’s income  
• Accessible, if the cost of transportation represented 5 – 10% of the patient income  
• Not accessible, if the cost of transportation represented more than 10% of the 
patient income  
Opinion about accessibility means self-report opinion about ARV drug accessibility by 
informant (HIV/AIDS patient and dispenser).  
Question was asked whether or not ARV drugs were accessible. The categorization of the 
positive answers was based on informant’s report or response in this manner: very accessible, 
accessible, less accessible and not accessible. 
Quality of dispensing was derived from evaluation of advices given to patients together with 
considerations of issue of confidentiality. The advices relates to directions given for usage of 
drugs (example, dosage and administration), side-effects, storage and new appointment. 
Questions were asked whether or not the informants gave (dispensers) or received (patients) 
advices. It is considered that confidentiality should be a prerequisite for good dispensing. The 
quality of dispensing was categorized as poor, acceptable, good and very good based on the 
advices and management of confidentiality as follows: 
• Poor quality of dispensing: any advice without confidentiality  
• Acceptable quality of dispensing: confidentiality with one advice  
• Good quality of dispensing: confidentiality with two or three advices   
• Very good quality of dispensing: confidentiality with more than three advices   
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The main issue in our study was to find out if the manner of drug dispensing, with emphasis 
on confidentiality, was a difficulty to access ARV drugs.  After data collection, we reviewed 
the categorisation of the quality of dispensing.  
Patient’s satisfaction with dispensing was based on the patient self-report on satisfaction 
with manner of dispensing. The categorization was: satisfied, less satisfied and not satisfied.  
Staff coverage for dispensing was based on the comparison between the numbers of 
HIV/AIDS patients to the number of drug dispensers, which could also explain the waiting 
time at the ARV sites. 
3.2.5 Recruitment and training of research assistant  
A male research assistant was recruited and trained for three days. The assistant was a 7th 
year student of the FMPOS doing his thesis on the nutritional aspect among HIV/AIDS 
patients. He had already acquired good experience on data collection, which facilitated our 
communication and collaboration. 
3.2.6 Workshop  
A workshop was organised with the French questionnaire which enabled us to discover 
meaningful ways of asking the patients in Bambara some important questions for our 
research. The workshop included one social anthropologist, one public health personnel, one 
dispenser from HPG, four representatives of HIV/AIDS patients from the three ARV sites and 
the two interviewers (main investigator and assistant). After the workshop, some changes 
were made to the questionnaire. 
3.2.7 Pilot test 
Prior to data collection, the questionnaire was pre-tested at Koulikoro ARV site, one of the 
main towns in Mali located 60km from Bamako. This pilot test helped to review the 
questionnaire and to check if it is understandable and acceptable by informant (HIV/AIDS 
patients and dispensers). The pre-test was done in September 2006 and concerned 18 
informants. The respondents were 17 patients and 1 dispenser.  
The choice of Koulikoro was motivated by the fact that it has approximately the same 
characteristics as Bamako. Bamako was avoided because the information could be spreaded 
out which could lead to bias. After the pilot test few improvements were made to the 
questionnaire. 
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3.2.8 Data collection and handling 
Face-to-face interviews were used to collect data, through questionnaires. Data was collected 
from October to November 2006 at the three ARV sites (HGT, CESAC and HPG).  
Both the main researcher and research assistant conducted the interviews. All interviews were 
done in French for dispensers as well as in Bambara language for the patients, except one 
patient from Sierra Leona who was interviewed in English.  
Since there was limited time, the interviewers (the principal investigator and the assistant) 
stayed at each treatment site until the number of patients needed had been obtained (43 for 
HGT, 106 for CESAC and 61 for HPG). The sites were randomly drawn for a working order 
in the data collection as follows: 
• First  HGT 
• Second CESAC  
• Third HPG. 
The interview of a patient was carried out at the end of the patient’s visit, that is, after 
collecting medication or sometimes during the waiting time before collection of the drugs at 
pharmacy level.  
The interviews at CESAC and HPG were conducted in private rooms allocated for this 
purpose such as the counselling room and room for HIV medicines storage. At the HGT, the 
office of the chief pharmacist was used for the interviews. 
All dispensers provided signed written consent whereas the patients provided either verbal 
consent or signed written consent (option of regular signature or thumb print). 
At the commencement of data collection, the main researcher and the research assistant 
jointly conducted the interviews. Thereafter, the interviewers became familiar with the 
questions and improved their ability to formulate questions in Bambara language. All the 
answers were reported in French and checked for conformity. After each interview (before the 
informant leaves) the interviewer checks for the completeness of data collected. The purpose 
was to complete any missing data in addition to facilitate evaluation of the response rate. For 
example, given that the interview was done anonymously, it would have been extremely 
difficult to trace the patient afterwards.  
At the end of each day, the interviewers convened a meeting to discuss challenges or any 
difficulties that were encountered in the field in order to find possible solutions. 
For the interviewees or participants, a token of 1500 Francs CFA (around 3 US dollars) was 
given to each person at the completion of the interview, as compensation.   
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The main researcher was responsible for storing the data safely and confidentially. It was only 
the local research team (main researcher, researcher assistant and local supervisor) that was 
allowed access to the data. The data was translated into English afterwards, while data 
processing took place during and after data collection. 
3.2.9 Data analysis 
Data were initially entered in EPIINFO version 6 and transferred in SPSS 14.0 for windows 
(Statistical Package for the Social Sciences version 14 for windows) 
The significance level was set at 0.05 for 95% of Confidence Interval (CI). 
A preliminary analysis using descriptive statistics and graphs were performed. Outliers were 
checked and data were cleaned. The following tests were used: 
• Independent test 
• Chi square test 
• Fisher Exact test 
• Univariate and Multivariate regressions 
3.2.10 Validity and reliability 
Validity means that the scientific observation actually measure what they intended to measure 
and that the conclusions are true. While, reliability means that someone else using the same 
methods in the same circumstances should be able to obtain the same findings implying that 
the findings are repeatable. (37). 
A workshop was organized and was followed by a pilot test which could increase the validity 
and reliability of the questionnaire. The English questionnaire was translated into French. The 
back translation into English permitted a check on the internal validity. Numerous studies in 
Mali have had interviews conducted in Bambara with the questionnaire written in French 
(38).  
It is noted that the responses to questions may be influenced by phrases or words used in the 
questions (39). In this case therefore, the questions were asked by using the same words in 
Bambara by the main researcher and the researcher assistant.   
The reliability of the study was assessed during the pre-test period through collection of the 
data by two people. The interviewers checked answers of informants which particularly 
helped to verify the conformity of the results. 
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3.2.11 Representativeness 
The HIV/AIDS patients in Bamako were not representative of the whole population of 
HIV/AIDS patients in Mali. However, this study samples are sufficiently representative to 
enable generalization of the result to the whole HIV/AIDS patients in Bamako under ART.  
3.3 Ethical clearance:  
3.3.1 Ethical approval 
The research project was approved by the Norwegian ethical committee (annex 7).  Also, 
ethical clearance was obtained from the Malian ethical committee of the FMPOS (annex 8). 
Before commencement of the research, the protocol was translated into French and closely 
followed by an oral presentation. The ethical committee’s observations have been taken into 
considerations. 
The researcher visited each ARV site (HGP, CESAC and HPG) to seek for permission to 
conduct the research before starting data collection in the three ARV sites (letter plus ethical 
approval from the Malian ethical committee of FMPOS and research protocol if necessary). 
Permission was obtained from these ARV sites.   
3.3.2 Informed consent 
Informed consent of HIV/AIDS patients and dispenser was sought and obtained. The 
participants were informed about the purpose of the study and the benefits of the findings. 
The name of the participant did not appear on the questionnaire, so as to guarantee 
confidentiality. Each participant got an ID number which is tied to a specific ARV site. Any 
information provided by an informant remained anonymous and confidential. Participants 
could withdraw at any time without penalty. 
A written consent was signed or thumb-printed. Where circumstance warrants, an oral 
acceptance would at least be secured from the participant after accepting voluntary 
participation. 
 After completing the interview, each participant received the sum of 1500 Francs CFA 
(around 20 NOK) as compensation in accordance with recommendation from the Malian 
ethical committee. 
3.4 Project management:  
The main researcher was the principal manager of the present project. The supervisors were 
the advisors during the entire process in the project. Contact was maintained through phone 
and internet communications during the fieldwork.  
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3.5 Dissemination of findings  
The report is written in English. However, a summary of the findings will be translated into 
French and sent to the MoH; the Malian ethical committee and the Swiss cooperation in Mali. 
A master thesis is prepared and submitted to the University of Oslo, Norway.  
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CHAPTER 4:  FINDINGS 
4.1 Demographic data and respondents’ characteristics 
There were 210 HIV/AIDS patients under ART for at least one month and 16 dispensers who 
were interviewed from the three ARV sites in Bamako (HGT, CESAC and HPG). 
4.1.1 Patients 
Table 2: Distribution of patients between the sites 
ARV site  Number % 
HGT 43 20.5 
CESAC 106 50.5 
HPG 61 29.0 
 
Gender 
Male
34%
Female
66%
 
Figure 4: Gender of patients 
 
As shown in Figure 4, 138 of the 210 patients (66%) were female, 72 were male (34%). This 
correlates with the Health and Demographic Survey (EDS III) of HIV prevalence 2.0% 
female and 1.3% male (3).  
 
 28
Age 
The patients were between 18 to 65 years old. The mean age was 35.17 ± 9.23 years. Figure 5 
shows the number of patients by age group. 
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Figure 5: Patients according to age group 
In Mali, the highest prevalence was 3.9% in the 30-34 years old age group in 2001(3).  
 
Marital status 
Table 3: Patients according to the marital status 
Marital status Number % 
Married 92 43.8 
Single 38 18.1 
Widowed 55 26.2 
Divorced 25 11.9 
Total 210 100.0 
 
In this study, 92 patients (43.8%) were married, 55 (26.2%) widowed. The singles and 
divorced are respectively represented as follows: 38 (18.1%) and 25 (11.9%).  
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Level of schooling 
The patients were categorized into five groups according to the length of their formal 
education: 
Non-schooling (0 year) 109  (51.9%) 
Primary school (1-6 years) 34             (16.2%) 
Junior high school (7-9 years) 26   (12.4%) 
Secondary school (10-12 years) 37   (17.6%) 
Higher education (> 12 years) 4   (1.9%) 
In Mali the literacy rate was estimated to be 19% in 2004 (2).  
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Figure 6: Profession of the patients under ARV treatment 
 
Only 43 respondents (20.5%) were wage earners while 100 (47.6%) were unemployed. Out of 
these 100 jobless 47 (47%) were housewives.  
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Residence 
Bamako
87%
Outside Bamako
13%
 
Figure 7: Residence of the HIV/AIDS patients 
 
The majority of the patients 183 (87%) were residing in Bamako while only 27  
(13%) were coming from outside Bamako. 
Table 4: Distribution of patients between the 6 communes of Bamako 
Communes Number % 
Commune I 51 27.9 
Commune II 22 12.0 
Commune III 16  8.7 
Commune IV 31 16.9 
Commune V 29 15.8 
Commune VI 34 18.6 
Total 183 100 
 
Income 
The average monthly income was 60 045.85 FCFA ± 51 668.07. The income ranged between 
7 000 to 315 000 Francs CFA (approximately 14 – 630 dollars US). 
NB: 1 dollar US ≈ 500 Francs CFA 
120 patients (57%) had no income while 90 (43%) had an income. 
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Figure 8: Distribution of the patients according to the income level 
 
The categorisation of the income level was as fellows: 
• No income = 0 Franc CFA     120  (57%)  
• Low income from 7 000 to 50 000 Francs CFA  49 (24%)  
• Moderate income from 50 005 to 100 000 Francs CFA 31 (15%) 
• High income above 100 000 Francs CFA   8  (4%) 
 
Out of 120 patients without income, 105 (87.5%) received family help to meet their basic 
needs while 11 (9%) used mutual-help. The remaining 4 did part-time jobs such as laundry, 
sale of cold water, alms and fortune-telling. 
 
Duration of ART 
The patients started treatment from 1 month to 6 years; the mean was 16.45 ± 13.78 months.   
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Figure 9: Duration of ARV treatment by year 
 
119 patients (56.7%) were under ARV for one year or less, 51 (24.3%) for 2 years or less and 
27 (12.9%) for 3 years or less. 
 
Frequency of ARV reception  
107 patients (51%) received their medication each month while 98 (46.6%) received their 
medication every two months. Only 5 patients (2.4%) received their medication quarterly.  
 
Living conditions  
The majority of patients had radio 160 (76.2%) and TV 118 (56.2%) at home. 
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Opinion about the distance from the ARV site 
Far
60%
No far
40%
 
Figure 10: Distance to the ARV site according to patient opinion 
125 patients (60%) thought that they lived far from the ARV site while 85 (40%) felt the 
opposite. 
Opinion on the time spent to reach ARV site 
Not long
46%
Long
54%
 
Figure 11: Time spent to reach the ARV site 
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According to the opinion about the time spent to reach ARV site, 113 patients (54%) 
responded that they spent longer time while 97 (46%) did not spend long time. 
 
Time spent to get ARV in the treatment site 
 Not much 
46%
Much
54%
 
Figure 12: Opinion on the time spent to get ARV in the treatment site 
 
When asked if they thought that it took a long time to get ARV, 113 patients (54%) of the 
responded that they spent long time while 97 (46%) did not spend long time. 
 
Time spent to get ARV drugs 
≤ 1 hour
56%
≤ 2 Hours
15%
≤ 3 Hours
17%
≤ 4 Hours
10%
≤ 5 Hours
2%
 
Figure 13: Time spent to get ARV drugs in hours 
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The time to get drugs at ARV dispensing ranged from 3 to 300min (0.05 to 5hours). 117 
patients (56%) spent one hour or less to get ARV.   
 
Time spent to get medical prescription in hours 
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Figure 14: Time spent to get medical prescription in hours 
 
The time to get medical prescription at treatment site ranged from 3 to 300min  
(0.05 - 5hours). 75 patients (35%) spent one hour or less to get a prescription sheet, 39 (19%) 
had 2 hours or less. 96 patients (46%) spent 3 hours or more. 
The time to get prescription was longer than the time took to get ARV as mentioned by 
the HIV/AIDS patients during the workshop. 
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Waiting time at the treatment sites in hours 
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Figure 15: Waiting time at the treatment sites in hours 
 
The waiting time at the treatment site was the time spent to get a medical prescription plus the 
time spent to get ARV. This time ranged from 6 to 600min (0.10 to 10 hours). 127 patients 
(60%) spent 4 hours or less as waiting time and 35 (17%) more than 6 hours. 
 
Means of transportation 
No own means 
82%
 Yes own means 
18%
 
Figure 16: Possession of means of transportation 
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The majority of the patients 172 (82%) did not have their own means of transportation. Only 
38 patients (18%) had their own means and among them 35 (92%) had a motorbike while 3 
(8%) had a car. 
Table 5: Distribution of the means of transportation 
Means of transportation 
 
Number % 
Motorbike 35 16.6 
Car 3   1.4 
Minibus 90 42.9 
Bus 20   9.5 
Minibus + Taxi 37 17.6 
Taxi 9   4.3 
Bus +Taxi 8   3.8 
By foot 5   2.4 
Minibus + Taxi + Bus 1   0.5 
Bus +Taxi + Car 1   0.5 
Job’s car 1   0.5 
Total 210 100.0 
 
166 patients (96%) out of 172 who had no means of transportation used public transportation 
to reach ARV site. 90 patients (42.9%) used a minibus as means of transportation, 20 patients 
(9.5%)  took a bus. 37 patients (17.6%) used a taxi plus minibus to reach the treatment site at 
the same time. Only 5 patients (2.4%) walked while 1 patient used his job’s car to get his 
medication.  
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Money spent on food 
Did not spend
57%
 Spent
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Figure 17: Money spent on food by patients 
 
120 patients (57%) did not spend money to buy food while waiting to get ARV drugs or after; 
whereas 90 (43%) spent money. 
The reason was that the long waiting time made them miss their main meal at home.   
Existence of other difficulties to get ARV 
Yes 
26%
No 
74%
 
Figure 18: Opinion about difficulties 
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In addition to the difficulties already mentioned, the majority of patients 155 (74%) in open-
ended question did not see any difficulty that prevented them from getting ARV while 55 
(26%) mentioned other difficulties.  
Table 6: Difficulties mentioned by patients 
Difficulties mentioned by 
patients  
Number % 
Lack of money 15 27.3 
Long waiting time 11 20.0 
Stigma 6 10.9 
Difficulty in obtaining 
permission to leave job  4   7.3 
Difficulty of transportation 2    3.3 
Health center 1    1.8 
Health staff 1    1.8 
Other 15    27.3 
Total 55 100.0 
 
The main difficulties were related to lack of money, long waiting time, stigma and difficulty 
to obtain permission to leave job because of non-disclosure of the patients HIV status.  
 
The other difficulties mentioned were  
• The long distance to reach the ARV site had been cited 
• One patient complained about the location of CESAC site  near the market because he 
was ashamed and worried about being seen 
• Having to get very early to the site in the morning for laboratory appointment 
• Separate appointments were made for medication and laboratory tests (initiating 
treatment and follow-up) which means having to travel for laboratory test in addition 
to travel for medication 
• One patient did not know the town and usually was accompanied by a brother who 
was very busy 
• Lack of someone who could take care of the children during the patient absence to get 
the medication at the ARV site 
• For one other patient it was only disease which can prevent to travel for medication 
Some patients mentioned the combination of several of these difficulties.  
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Opinion about accessibility of ARV 
Table 7: Opinion about accessibility of ARV drugs 
ARV accessibility 
 
Number % 
Accessible 206 98.1 
Not accessible 4 1.9 
Total 210 100.0 
 
206 patients (98%) responded that ARV were accessible in our study which means they did 
not face major difficulties to get ARV against 4 (2%) who said that it is not accessible. The 
main reasons according to those who had no access were  
• The waiting time at the treatment site 
• The medical prescription being made compulsory 
• The doctors appointment being made compulsory 
• The waiting time and the distance to the treatment site. 
 
Level of ARV accessibility 
Less accessible
23%
Very Accessible
11%
Accessible
66%
 
Figure 19: Opinion about the level of ARV accessibility 
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When asked to give the level of accessibility of ARV drugs, 136 patients out of 206 (66%) 
maintained that ARV was accessible while 23 patients (11%) thought that ARV was very 
accessible. However, for 47 patients (23%), ARV was less accessible. 
 
Suggestions for better access for ARV 
Table 8: Suggestions for better access for ARV by patients 
Suggestions for better access to ARV Number % 
Reduce the waiting time 40 78.2 
Decentralize ARV sites  5 9.8 
Assure or guarantee refund of transportation cost 1 2.0 
Make ARV available at private pharmacies 1 2.0 
Make all drugs free for opportunistic infections 1 2.0 
Initiate early medical check-ups 1 2.0 
Make doctors more accessible 1 2.0 
Reduce lack of comprehension dispenser/patient 1 2.0 
Total 51 100.0 
 
The patients who responded that ARV drugs were less or not accessible were asked about 
their suggestion on how access could be improved (less accessible 47 patients and not 
accessible 4 patients). 
Forty patients out of 51 (78.2%) wanted the reduction of the waiting time at the ARV site 
while 5 patients (9.8%) suggested the decentralisation of the ARV sites. 
The other patients thought that in addition to free ARV, all drugs for opportunistic infections 
should be free of charge for HIV/AIDS patients; the transportation cost should be covered; 
ARV should also be accessible at private pharmacies level etc. 
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Presence of people during the dispensing 
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61%
Yes 
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Figure 20: Receiving ARVs in presence of other people 
 
129 patients (61%) maintained that ARV was not given in presence of other people while for 
81 (39%) it was done in presence of other people.  
These other people were the health staff. There were 2 (55.6%), 3 (33.3%) or 4 (11.1%) 
during the dispensing according to patients. 
 
Opinion about the presence of other people during the dispensing 
 confortable with
95%
Not confortable 
with
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Figure 21: Opinion about the presence of other people during the dispensing 
 43
 
77 patients (95%) out of 81 who received their ARV drugs in presence of other people (health 
staff) were comfortable with this presence while 4 (5%) were not comfortable. Moreover, one 
patient was ashamed about the presence of many health workers. 
4.1.2 Dispensers 
Sixteen dispensers were interviewed during the data collection in the three ARV sites 
Table 9: Distribution of the 16 dispensers between the ARV sites 
ARV sites  Number % 
HGT 9 56.3 
CESAC 3 18.7 
HPG 4 25.0 
Total 16 100 
 
This was the staff doing the dispensing at the time of data collection. In practice however, the 
staff permanently allocated for dispensing were the following: 
• 1 dispenser for HGT  
• 1 dispenser for CESAC 
• 2 dispensers for HPG 
Gender 
With a total number of 16 dispensers, 14 (87.5%) were male while 2 (12.5%) were female.  
Age 
The ages of the dispensers ranged from 25 to 35 years. The mean age was 28.63 ± 3.26 years.  
Qualification of dispenser 
Seven dispensers (44%) were pharmacists while the others were respectively 7th year 
pharmacy students 5 (31%) and 6th year pharmacy students 4 (25%). They were doing their 
thesis in the ARV sites which means they were not employed at the dispensing site. 
Training on ARV dispensing 
11 dispensers (69%) had received training on ARV dispensing while 4 (31%) did not received 
any training. They did the dispensing based on their practice in the ARV sites. 
Involvement on ARV dispensing 
The experience on ARV dispensing ranged from 2 to 72 months. The median was 12 months. 
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4.2 Descriptive Statistics for some variables 
Table 10: Descriptive statistics for patients attending all three ARV sites 
 Variables N Minimum Maximum Mean/Median 
Distance to reach ARV 
site (in km) 210 1 1200 9 
Time spent to reach ARV 
site (in min) 208 10 2400 100.64 
Transportation cost 209 0 21700 500 
Time spent to get medical 
prescription (in min) 210 3 300 133.82 
Time spent to get ARV 
(in min) 210 3 300 94.43 
Waiting time (in min) 210 6 600 228.26 
Waiting time (in hour) 
210 0.10 10 3.80 
 
The mean was used when the data were normally distributed. The median was used when the 
data were not normally distributed because it is not influenced by extreme values (40). 
The median was used for the distance to reach ARV site 9km and the transportation cost 500 
Francs CFA (≈1 dollar US). 
The mean was used for the time to reach ARV site, the time to get medical prescription, the 
time to get ARV and the waiting time (for medical prescription and ARV dispensing).  
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4.3 Advices during ARV dispensing 
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Figure 22: Comparison of advices as reported by patients and dispensers  
 
This figure shows the advices received by patients and given by dispensers.  
207 patients (98.5%) received advices on directions for drug use (dosage and administration); 
73 (34.8%) on side-effects; 15 (7.1%) on storage; and 84 (40%) on new appointment. 
16 dispensers (100%) gave advices on directions for use and side-effects; 10 (62.5%) on 
storage; and 13 (81.2%) on new appointment. 
The responses to the question on advices received by patients and given by dispensers were 
not consistent. The dispensers said that they gave almost all the advices: directions for use 
(dosage and administration), side-effects, storage, new appointment and even other advices 
such as compliance, sexual and nutritional advices etc. However the dispensers did not 
emphasis on appointment because it was done by the medical doctors and written on the 
prescription sheet. The regular appointment given by the medical doctor enabled follow-ups 
on the patients (clinical and biological parameters). The few appointments were given in 
terms of reminder. 
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91/210 patients said that they received other advices in addition to those mentioned above. 89 
out of 91 (97.8%) received advice about treatment compliance; 1 (1.1%) nutritional advice 
and 1 (1.1%) sexual advice. 
11/16 dispensers said that they gave other advices.  5 dispensers out of 11 (31.3%) gave 
advice about treatment compliance; 3 (18.8%) sexual advice; 1 (6.3%) drug interaction; 1 
(6.3%) sexual plus psychological support and 1 (6.3%) compliance plus nutritional advice. 
4.4 Univariate descriptive statistics 
Table 11: Estimated means test by ARV site 
Variables 
Name of ARV 
site Mean Sig. 95% Confidence Interval 
        Lower Bound Upper Bound 
HGT 22950.000 0.0001 9170.418 36729.582
CESAC 18391.509 0.0001 9926.780 26856.239
Value of monthly 
income 
HPG 39900.583 0.0001 28649.602 51151.565
HGT 37.875 0.07 -3.613 79.363
CESAC 19.132 0.140 -6.354 44.618
Distance covered to 
reach ARV site 
 (in km) HPG 87.883 0.0001 54.008 121.758
HGT 102.500 0.004 32.954 172.046
CESAC 61.651 0.005 18.929 104.373
Time spent to reach 
ARV site  
(in min) HPG 169.750 0.0001 112.966 226.534
HGT 20.325 0.036 1.336 39.314
CESAC 151.415 0.0001 139.750 163.080
Time spent to get 
ARV 
 (in min) HPG 46.467 0.0001 30.962 61.971
HGT 38.700 0.001 16.628 60.772
CESAC 174.575 0.0001 161.017 188.134
Time to get medical 
prescription 
 (in min) HPG 130.833 0.0001 112.812 148.855
HGT 59.025 0.002 21.703 96.347
CESAC 325.991 0.0001 303.064 348.917
Waiting time (in 
min) 
  HPG 177.300 0.0001 146.827 207.773
HGT .984 0.002 .362 1.606
CESAC 5.433 0.0001 5.051 5.815
Waiting time (in 
hour) 
  HPG 2.955 0.0001 2.447 3.463
HGT 1037.625 0.01 240.301 1834.949
CESAC 689.151 0.006 199.359 1178.943
Transportation cost 
in FCFA (local 
currency in Mali) HPG 2639.333 0.0001 1988.321 3290.346
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The patients from HPG had the highest level of income followed by HGT and CESAC. 
It was easier to reach CESAC than the other two sites. 
HPG was still the site which took the longest time to reach followed by HGT and CESAC.   
The longest time spent in getting ARV was at CESAC followed by HPG and HGT. 
The longest time spent in getting medical prescription was at CESAC followed by HPG and 
HGT. 
CESAC had the longest waiting time followed by HPG and HGT. 
The highest cost of transportation was experienced in journeys to HPG followed by HGT and 
CESAC. 
4.5 Dependant variables 
4.5.1 Geographical accessibility 
4.5.1.1 Geographical accessibility by distance covered to reach ARV site 
Very 
24%
Access
54%
Less 
9%
Not 
13%
 
Figure 23: Geographical accessibility by distance covered to reach ARV site 
 
The categorisation of the geographical accessibility by distance covered was done according 
to the distance covered by patients to reach the ARV site: 
• Very accessible (≤ 5km) for 50 patients (24%) 
• Accessible (>5 - ≤ 15km) for 114 patients (54%) 
• Less accessible (> 15 - ≤ 30km) for 19 patients (9%) 
• Not accessible (> 30km) for 27 patients (13%) 
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4.5.1.2  Geographical accessibility by time spent to reach ARV site 
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Figure 24: Geographical accessibility by time spent 
 
The categorisation of the geographical accessibility by time spent was done according to the 
time spent by patient to reach the ARV site:  
• Very accessible (≤ 30min) for 47 patients (23%) 
• Accessible (31- 60min) for 100 patients (48%) 
• Less accessible (61- 180 min) for 46 patients (22%) 
• Not accessible (> 180 min) for 15 patients (8%) 
4.5.2 Financial accessibility 
Table 12:  Financial accessibility of ARV by patients 
Financial accessibility Number % 
Very accessible (< 5%) 72 82.8 
Accessible (5 - 10%) 8 9.2 
Not accessible (> 10%) 7 8.0 
Total 87 100 
 
The financial accessibility was the cost of transportation in percentage of patient’s income.  
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In this case ARV was accessible for the majority of the patients 80 (92%) who had an income 
and from whom we obtained information on the income value. The ARV was not accessible 
for only 7 patients (8%). 
4.5.3 Opinion of informants about accessibility of ARV 
a) Patients 
The following categorisations were done according to patients responses 
- Very accessible  23 (10.9%) 
- Accessible  136 (64.8%) 
- Less accessible  47 (22.4%) 
- Not accessible  4 (1.2%) 
b) Dispensers 
The dispensers’ opinions were categorised as following 
- Very accessible  2 (12.5%) 
- Accessible  11 (68.7%) 
- Less accessible  1 (6.3%) 
- Not accessible  1 (6.3%) 
- No opinion  1 (6.3%) 
4.5.4 Quality of dispensing 
Table 13: Quality of dispensing 
Quality of dispensing Number % 
Poor quality (≤ 3) 69 32.9 
Acceptable quality (4-5) 114 54.2 
Good quality (>5) 27 12.9 
Total 210 100.0 
 
After data collection, we reviewed the categorisation of the quality of dispensing. 
Confidentiality was not a concern for patients. The appointment was given by the medical 
doctor. In this case we emphasized principally on the directions for use (dosage and 
administration) and the side-effects. The scores were attributed in terms of importance of 
advices as follows: 
• Directions for use    3 
• Side-effects     2 
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• Storage     1 
• Reminder about new appointment  1 
The quality of dispensing was categorised according to the number of scores. 114 patients 
(54.2%) received an acceptable quality of dispensing, 69 (32.9%) had a poor quality. Only 27 
patients (12.9%) received a good quality of dispensing 
4.5.5 Patient’s satisfaction with dispensing manner 
Satisfied
84%
Not satisfied
14%
Less satisfied
2%
 
Figure 25: Opinion of the patients about dispensing manner 
 
176 patients (84%) were satisfied about the dispensing manner (friendly service) while 30 
(14%) were not satisfied. Only 4 (2%) were less satisfied. 
4.5.6 Staff coverage for dispensing 
The staff coverage for dispensing during the data collection was estimated by the ratio of 
patients/dispensers which was the following: 6 343/16 = 396 patients per dispenser. 
By ARV site the ratio was the following: 
• HGT  1 299/9 = 144 
• CESAC  3 199/3 = 1 066 
• HPG  1 845/4 = 461 
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This ratio could explain the long waiting time at the dispensing site. This waiting time could 
be even longer without any help from assistants (6 and 7th year Pharmacy students).  
By considering only the staff allocated for dispensing (permanently assigned staff) at HGT 
and CESAC it was really all patients for one dispenser while in HPG the patients was divided 
between the two dispensers 3 199/2 = 1 600 patients.    
4.6 Analytical findings 
Table 14: Geographical accessibility by distance covered for each dispensing site 
Name of ARV site Total Geographical accessibility by distance 
covered (in km) HGT CESAC HPG   
12 36 2 50 
Very accessible (≤ 5km) 
28.0% 33.9% 3.3% 23.8% 
25 59 30 114 
Accessible (>5 - ≤ 15km) 
58.1% 55.7% 49.2% 54.3% 
1 4 14 19 
Less accessible (> 15 - ≤ 30km) 
2.3% 3.8% 22.9% 9.0% 
5 7 15 27 
Not accessible (> 30km) 
11.6% 6.6% 24.6% 12.9% 
43 106 61 210 
Total 
100.0% 100.0% 100.0% 100.0% 
 
The comparison between the ARV sites by geographical accessibility in terms of distance 
covered by patients to reach the sites was investigated by using Fisher’s Exact test. The test 
revealed a statistically significant difference to reach the ARV sites in Bamako p < 0.05.  
HPG was the least accessible dispensing site with the longest distance covered by patients. 
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Table 15: Geographical accessibility by time spent for each dispensing site 
Name of ARV site Total Geographical accessibility by 
time spent (in min) HGT CESAC HPG   
8 31 8 47 
Very accessible (≤ 30min) 
19.5% 29.0% 13.1% 23.0% 
22 55 23 100 
Accessible (31- 60min)  
53.7% 52.0% 37.7% 48.0% 
8 18 20 46 
Less accessible (61- 180 min)  
19.5% 17.0% 32.8% 22.0% 
3 2 10 15 
Not accessible (> 180 min)  
7.3% 2.0% 16.4% 7.0% 
41 106 61 208 
Total 
100.0% 100.0% 100.0% 100.0% 
 
The comparison between the ARV sites by geographical accessibility in terms of time spent 
by patients to reach the sites was investigated by using Fisher’s Exact test. The test revealed a 
statistically significant difference between the sites. HPG was still the geographically least 
accessible dispensing site, with the time spent to reach the site ranging between 10 min to 
2400 min p < 0.05 
Table 16: Financial accessibility for each dispensing site 
Name of ARV site Total 
Financial accessibility of ARV 
HGT CESAC HPG   
 13 38 21 72 
  
Very accessible (< 5%) 
65.% 95.0% 78.0% 83.0% 
  4 1 3 8 
  
Accessible (5 - 10%) 
20.0% 2.5% 11.0% 9.0% 
  3 1 3 7 
  
Not accessible (> 10%) 
15.0% 2.5% 11.0% 8.0% 
20 40 27 87 
Total 
100.0% 100.0% 100.0% 100.0% 
 
A Fisher’s Exact test was conducted to compare the financial accessibility of the sites. The 
test revealed a statistically significant difference between the sites p < 0.05.  
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The lack of income could constitute a real problem for access to the sites. CESAC was the 
most accessible site financially. 
Table 17: The opinion of the patients on the dispensing manner for each ARV site 
Name of ARV site Total 
Opinion on the dispensing manner 
HGT CESAC HPG  
  Satisfied   39 82 55 176
      90.7% 77.4% 90.0% 83.8%
  Less satisfied   0 1 3 4
      .0% 0.9% 5.0% 1.9%
  Not satisfied   4 23 3 30
      9.3% 21.7% 5.0% 14.3%
Total   43 106 61 210
    100.0% 100.0% 100.0% 100.0%
 
The comparison between the ARV sites about the satisfaction with manner of drug dispensing 
was assessed by using Fisher’s Exact test. The test revealed a statistically significant 
difference between the sites p < 0.05. It was shown that 23 patients (21.7%) from CESAC had 
the most complaints about the manner of drug dispensing. But in all the three ARV sites the 
majority of the patients were satisfied. 
Table 18: Opinion on the time spent to get ARV for each ARV site 
Name of ARV site Total 
Long time to get ARV 
HGT CESAC HPG   
  7 72 18 97 
  
Yes 
16.3% 68.0% 29.5% 46.2% 
  36 34 43 113 
  
No 
87.3% 32.0% 70.5% 53.8% 
43 106 61 210 
Total 
100.0% 100.0% 100.0% 100.0% 
 
72 patients (68%) from CESAC said that they spent a long time in getting ARV while 36 
(87.3%) and 43 (70.5%) patients at HGT and HPG respectively did not spend long time. 
A Chi-square test revealed a statistically significant difference between the sites p < 0.05. 
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Table 19: Means of transportation by ARV site 
Name of ARV site Number % 
 HGT By foot 3 7.0 
  Bus 5 11.6 
  Taxi 3 7.0 
  Car 1 2.3 
  Motorbike 9 20.9 
  Minibus 20 46.5 
  Bus + Taxi  2 4.7 
  Total 43 100.0 
 CESAC By foot  2 1.9 
  Bus 13 12.3 
  Taxi  3 2.8 
  Motorbike 21 19.8 
  Minibus 67 63.2 
  Total 106 100.0 
 HPG Bus    2 3.3 
  Taxi   3 4.9 
  Car   2 3.3 
  Taxi +Minibus 37 60.7 
  Motorbike 5 8.2 
  Bus + Taxi 1 1.6 
  Taxi + Bus + Minibus 8 13.1 
  Taxi + Bus + Car 2 3.3 
  Job's car 1 1.6 
  Total 61 100.0 
 
48 patients from HPG (78.7%) used more than one means of transportation for travelling. 
 
Opinions on ARV accessibility and presence of other people during dispensing 
A Fisher’s Exact test was conducted to compare opinions of patients on the presence of other 
people (health staff) during the dispensing of ARV.  
The test revealed no statistically significant difference between the groups p > 0.05. This 
means that the presence of health staff during the dispensing did not influence the opinion of 
patients about ARV drugs accessibility. We can assume probably that there is not a concern or 
problem of confidentiality during the dispensing. 
 
Time to get ARV and opinion about time spent 
A Chi-square test was conducted to compare the time spent by patient to get ARV at the 
treatment site and the opinion of the patients about this time. The test revealed a statistically 
significant difference between the groups p < 0.05.  
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Of the patients who had to wait longer than 60 min, more got tired of waiting than those with 
less than 60 min waiting time. 
Table 20: Association between the means of transportation and having an income 
Income Total 
Means of transportation  
No Yes   
6 32 38 
Own or personal means 
5.0% 35.6% 18.1% 
111 55 166 
Public means 
92.5% 61.1% 79.0% 
3 2 5 
By foot 
2.5% 2.2% 2.4% 
0 1 1 
Job car 
.0% 1.1% 0.5% 
120 90 210 
Total 
100.0% 100.0% 100.0% 
 
A Fisher’s Exact test was conducted to see the association of the means of transportation used 
by patients to reach ARV sites and the existence of an income. The test revealed a statistically 
significant difference between the groups of income and no income p < 0.05. 
In the 2 X 2 comparison of the patients under ART using their own means and those using 
public ones, having an income had a influence P=0.00000001 (highly significant). 32 patients 
(35.6%) who had had an income used their own means of transportation to reach ARV sites. 
The majority of patients who had no income 111 (92.5%) used public means of transportation  
Association of waiting time and expense at the treatment sites 
An independent-samples t-test was conducted to compare the waiting time of patients at the 
treatment sites and the expense for food or/and drink. The test revealed a statistically 
significant difference between the groups p < 0.05 
The longer the waiting time was, the more money they spent to buy food at the treatment site, 
and this came in addition to the transportation cost. 
The expenses were proportional to the length of waiting time to get ARV. 
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Opinion on ARV access and existence of other difficulties 
Almost all the patients 154 (99%) who responded that there were no other difficulties that 
prevent them from getting ARV thought that ARV was accessible. Despite that, 204 patients 
(98%) responded that ARV was accessible even though some difficulties still exist. The main 
difficulties were related to the lack of money, the long waiting time and stigma Fisher’s exact 
test, p < 0.05 
 
Comparison of income and spending for transportation  
 
Table 21: Income and transportation fee 
Income Payment of transportation fee 
by who  No Yes 
Total 
  
 No fee 3 4 7 
    2.5% 4.4% 3.3% 
  Myself 30 78 108 
    25.0% 86.7% 51.4% 
  Husband 23 4 27 
    19.2% 4.4% 12.9% 
  Brother 22 4 26 
    18.3% 4.4% 12.4% 
  Sister 12 0 12 
    10.0% .0% 5.7% 
  Friend 7 0 7 
    5.8% .0% 3.3% 
  Other 9 0 9 
    7.5% .0% 4.3% 
  Father 9 0 9 
    7.5% .0% 4.3% 
  Son 5 0 5 
    4.2% .0% 2.4% 
Total 120 90 210 
  100.0% 100.0% 100.0% 
 
78 patients (86.7%) out of 90 who had an income paid the transportation fee themselves. 
However for those who had no income, their transportation fee was paid mainly by 
themselves 30 (25.0%), husband 23 (19.2%), brother 22 (18.3%) and sister 12 (10.0%). 
The lack of income could be a major cause of the under frequentation of the treatment site  
 Fisher’s exact test, p < 0.05. 
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4.7 Gender analysis 
 
Marital status by gender 
40%
55%
16%
20%
60%
45%
84%
80%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Married Single Widowed Divorced
Male Female
 
 
Figure 26: Marital status according to gender 
 
The majority of widowed patients was female 46/55 (84%) and divorced 20/25 (80%).  
Among the divorced female, 6/20 (30%) were abandon by their husband. 
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Means of transportation by gender  
Table 22: Means of transportation according to gender 
Gender Total 
Means of transportation male female   
29 9 38  Own means 
40.3% 6.5% 18.1% 
41 125 166  Public means 
56.9% 90.5% 79.0% 
1 4 5  By foot 
1.4% 3.0% 2.4% 
1 0 1  Job car 
1.4% .0% 0.5% 
72 138 210 Total 
  100.0% 100.0% 100.0% 
 
Males and females used different means of transportation to reach the ARV sites. The 
Fisher’s Exact revealed a statistically significant difference between the gender p < 0.05. 
However, in the 2 X 2 comparison of the use of the own means and public means between 
gender, the majority of female 125 (90.5%) used public means to reach the ARV sites while it 
was 41 males (56.9%). 29 male patients (40.3%) had their own means of transportation while 
it was only 9 female patients (6.75%) p=0.000001 (highly significant). 
 
 
 
 
 
 
 
 
 
 
 
 
 59
Income by gender 
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Figure 27: Comparison of patients’ income by gender 
 
There was a difference between the genders in terms of income. There were significantly 
more males than females in the moderate and high income categories, 20 (64.5%) and 6 
(75%) respectively. The majority of the female patients 95 (79%) had no income while only 
25 (21%) male patients had no income. The Fisher’s Exact test revealed a statistically 
significant difference between the gender p < 0.05. 
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Summary of some answers and opinions according to gender 
 
Chi-square or Fisher Exact test was used to find gender difference for some answers and 
opinions.  
We did not show any significant difference between genders (p > 0.05) for the following 
variables:  
• Quality of dispensing 
• Directions for use 
• Side-effects 
• Storage 
• Opinion on dispensing manner 
• Frequency of ARV reception 
• Financial accessibility 
• Time spent to get prescription (in hour) 
• Time spent to get ARV (in hour)  
• Waiting time (in hour)  
However, for advice on new appointment there was difference between male and female  
p < 0.05. The majority of male patients 51 (71%) did not received this advice. 63 female 
patients (46%) received it against 21 male patients (29%).    
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CHAPTER 5: DISCUSSION 
The aim of this study was to assess potential difficulties which can limit ARV drugs access 
even though these drugs are free of charge for HIV/AIDS patients at the treatment site in 
Bamako, Republic of Mali.  
A cross sectional survey was used. The material was a questionnaire administered through a 
face-to-face interview with the participants. The questionnaire was constructed in open and 
closed questions. The interviews were performed in Bambara (language of Bambara ethnic 
group) for patients and in French for dispensers.  
The validity and reliability were discussed in the methodology part. 
5.1 Strengths of the study: 
Cross-sectional survey is a suitable design when little is known of the phenomenon under 
investigation.  
The workshop and the pilot test helped to find an understandable way to ask questions. The 
face-to-face interviews provided a high rate of response. The interviews did not reveal any 
major communication barrier. The questionnaire assured the confidentiality of the 
information.  
Our findings give baseline data which can help policy-makers to improve ARV drugs 
accessibility even though these are free of charge to HIV/AIDS patients. 
5.2 Limitations 
Some patients still do not have access to ARV and our study did not address this group of 
patients. The study did not reach the patients who missed their appointments nor those who 
came on Saturday for special reasons. Because of this, the findings can not be generalised at 
the country level. This study was conducted in Bamako where there were several means of 
transportation and good roads. Future studies are needed in the regional sites to assess the 
general accessibility of ARV in Mali. 
Health facility based study may be easier to conduct, but the results may not be representative 
of the entire population of HIV/AIDS patients.  
Our study did not include the PMTCT sites which dispense mostly mono-therapy. PMTCT 
concerns pregnant women who were not included in our study. 
Convenience sampling (non-probability sampling) was used which is not optimal for a survey 
and limits the generalisation of the findings. The interviews were done consecutively at the 
dispensing sites.  
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5.3 Discussion of findings 
5.3.1 Characteristics of the respondents  
210 HIV/AIDS patients under ART for at least one month and 16 dispensers were interviewed 
from the three ARV sites in Bamako (HGT, CESAC and HPG). 
a) Patients 
The majority of the patients 138 (66%) were female. The national HIV prevalence rate was 
1.7%. 2.0% for female and 1.3% for male(3). 
The patients were between 18 and 65 years old. In Mali, the highest prevalence was 3.9% in 
the 30-34 age group in 2001. The district of Bamako, with 2.5%, had the highest rate of HIV 
prevalence inside the country followed by the regions of Kayes, Ségou and Koulikoro 1.9% 
each (3). 
In this study, 92 patients (43.8%) were married, 55 (26.2%) widowed and 25 (11.9%) 
divorced. 
109 patients (51.9%) were illiterate which is lower than the general illiteracy rate in Mali 
which was 81% in 2004 (2).  
Only 43 patients (20.5%) were wage earners and had regular income while 100 (47.6%) were 
unemployed. Out of these 100 jobless 47 (47%) were housewives.  
120 patients (57%) out of 210 had no income. 105 (87.5%) of those without income received 
family help to meet their basic needs in addition to the transportation cost. In Mali the social 
network is very important where the health insurance is not extended to the whole population.   
The majority of the patients 183 (87%) were residing in Bamako and distributed between the 
six communes of Bamako while the ARV sites were located only in second (HGT) and third 
(CESAC and HPG) communes. Several patients inside or outside Bamako could go to the 
nearest site or regional ones which will be easier to reach in terms of distance, time and 
money. More over, one patient from the north of Mali travelled 1 200km to get his 
medication. This patient passed through 3 ARV sites (Gao, Mopti and Ségou) to reach 
Bamako. These patients tried to avoid stigma by travelling as far as possible from home.  
The decentralisation of ARV sites will improve the geographical and financial accessibility 
but will not solve the problem for those who want to avoid stigma. 
The majority of the patients 119 (56.7%) were under ARV for one year or less. 
107 patients (51%) received their medication each month while 98 (46.6%) did so every two 
months. Only 5 patients (2.4%) received their medication quarterly.  
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160 patients (76.2%) had radio and 118 (56.2%) had TV at home. This is an important 
observation because the awareness campaign on HIV is diffused through radio and TV 
emissions.  
b) Dispensers 
Sixteen dispensers were interviewed during the data collection in the three ARV sites (9 at 
HGT, 3 at CESAC and 4 at HPG). 
14 dispensers out of 16 (87.5%) were male. The ages of the dispensers ranged from 25 to 35 
years. 7 dispensers (44%) were pharmacists. They were helped by 6thor 7th year pharmacy 
students doing their thesis at the dispensing site.  
 The majority of dispensers 11 (69%) received training on ARV dispensing. The rest had an 
experience based on their practice in the ARV sites. There was no guideline to follow for 
ARV dispensing at the ARV sites. 
The experience on ARV dispensing ranged from 2 to 72 months. The regular staff 
(pharmacists allocated for dispensing) had the longer experience while the assistants’ 6th and 
7th year pharmacy students were working temporarily to finish their thesis at the dispensing 
site. 
5.3.2 Difficulties experienced 
 
Distance to ARV site 
The median distance was 9km. 50 patients (23.8%) had to travel 5km or less. A considerable 
number of patients on treatment 164 (78%) had to travel 15km or less to the treatment site. In 
Bamako 95% of the population had access to health care facilities within 5km and 99% within  
15km in 2004 (5). Access to health care is still low for HIV/AIDS patients. 
The travel distance to reach the treatment site ranged from 1 to 1200km while it was 1 to 
184km in Uganda and the maximum was 200km in Botswana (41). In Morocco (26), the 
distance was still a problem for the patients who lived far from the treatment site.  
 
Time to reach ARV site  
The travel time to reach the treatment site ranged from 10 to 2 400min. This time could not be 
justified knowing that Mali has at least one site in each of the main towns as follows: Kayes, 
Koulikoro, Sikasso, Ségou, Mopti, Toumbouctou, Gao and Kidal. Further, it takes less time 
for patients to reach some of these towns.  
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Means of transportation 
The majority of the patients 172 (82%) did not have their own means of transportation.  
166 patients (96%) out of 172 who had no means of transportation used public transportation 
to reach ARV site while only 5 patients (3%) preferred to walk. In Mali, walking is not 
preferred when one can afford other transportation, no matter how short is the distance.  
The fact is that 15 patients had only 2km or less of travel distance. In Morocco also only 3 
patients out of 88 walked to the treatment site (26). Among the other patients 63 used a bus, 
13 a train, 6 a taxi and 3 a car. This probably shows that the habit is not only Malian.    
90 patients (42.%) used a minibus as means of transportation which is very quick while bus 
was formal (regular schedule) and takes longer time even though it was more or less the same 
price as minibus.  
Having an income influenced also the means of transportation to reach the ARV site. The 
majority of patients who used public means of transportation 111 (67%) had no income.   
The majority of patients from HPG 48 (78.7%) used more than one means of transportation 
for travelling. 
 
Cost of transportation 
The transportation cost to the treatment site ranged from 0 to 21 700 Francs CFA. The median 
transportation cost was 500 Francs CFA (≈1 dollar US). In Tanzania (41), the transportation 
cost have been seen as a burden for some patients. However in Morocco (26), the cost of 
transportation was subsidized. The longer the distance was, the higher the transportation cost 
was.  
The majority of patients 92 (86.7%) who had an income paid the transportation cost 
themselves. Those who had no income had their transportation cost paid mainly by 
themselves or by the family’ members. Therefore lack of income could be a major cause of 
the under-utilization of the treatment site as it was reported in Morocco’ study. This is 
because AIDS can lead to dismissal from work, unemployment, discrimination etc. It is not 
enough to make ARV free of charge. There is an additional necessity for financial support 
(26). 
 
Waiting time/ Organisational issue 
The mean waiting time (waiting for medical prescription and ARV dispensing) was 3.8 ± 2.65 
hours. The waiting time ranged from 0.10 to 10 hours (6 to 600min). 
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Our findings showed that the major issue at the treatment site was the length of time spent or 
waiting time.  
The majority of patients 127 (60%) reported spending at least 4 hours at the treatment site. 
This is near to the Botswana study (41) which found that 53% of respondents spent at least 
four hours at the clinic. In Botswana, waiting time was found to be a challenge to adherence.  
In Uganda (same study) the average waiting time was 5 hours in the public facility and one 
hour in the private facility (41).  
 Even though the ARVs were made available and being provided free of charge at dispensing 
site, challenges still existed. Such challenges were found in: waiting time, cost of 
transportation to and from ARV site and cost of food while waiting to get ARV (41) 
The longer the waiting time was, the more the patients spent money to buy food at the 
treatment site. This also came in addition to the transportation fee. The reason was that the 
long waiting time made them miss the main meal at home. In Mali, usually people live in 
family and each member is required to be available or on time for meal unless there is a 
known reason for a family member’s absence.   
The expenses were proportional to the length of waiting time to get ARV. 
 
Unlike South Africa (42), in Mali ARV dispensing was under the responsibility of 
pharmacist. ARV was delivered by pharmacist or assistants (6 or 7th year student of pharmacy 
preparing their thesis). 
As in South Africa (42) the ARV was handed out on the basis of “first come, first served”. 
Usually, HIV/AIDS patients spent the whole day at the treatment site after arriving two hours 
ahead the opening time (7h 30 am) in Mali. But sick patients were prioritised and allowed to 
first see the medical doctor and also in getting ARV drugs.  
 
In Mali all patients were required to see a medical doctor to get a prescription before 
receiving the ARV. The medical prescription was also compulsory even for refill. This 
contributed to increasing the waiting time of the patients at the treatment site. While in South 
Africa (42), patients did not see a medical doctor unless it was necessary.  
5.3.3 Opinions of patients 
125 patients (60%) thought that they are living far from the ARV site. 
113 patients (54%) responded that they spent long time to reach ARV site.  
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Almost all patients 206 (98%) in our study responded that ARV were accessible which means 
they did not perceive any difficulty to get ARV.  
To the level of accessibility 47 patients out of 206 (23%) thought that ARV was less 
accessible.  
40 patients out of 51 (78.4%) who responded that ARV drugs were less or not accessible 
wanted the reduction of the waiting time at the ARV site while 5 patients (9.8%) suggested 
more decentralisation of the ARV sites inside the city of Bamako. 
81 patients (39%) received ARV in presence of other people (health staff) and the majority of 
them 77 (95%) was comfortable with this presence. This explains that the confidentiality was 
not a concern for patients which was opposite to the conclusion of Koumaré et al. (29).  
A possible reason for this is that the patients assume that health staff is obliged to protect the 
confidentiality of information about their patients. According to the International 
Pharmaceutical Federation (FIP) every country should have a code of ethics for pharmacists, 
obliging them to respect patient confidentiality (43). The national council of pharmacists of 
Mali is a member of FIP and had developed a national code of ethics. In Mali the protection 
of confidentiality is a general requirement for all health personnel.  
Despite that, the majority of patients responded that ARV was accessible even though some 
difficulties still exist. 55 patients out of 210 (26%) of noticed the existence of other 
difficulties that prevent to get ARV. The main difficulties that these patients notified were 
related to: the lack of money 15 (27%); long waiting time 11 (20%); stigma 6 (11%); and 
difficulty in obtaining permission to leave job because of non-disclosure of patient’s HIV 
status 4 (7%). 
5.3.4 Dispensing manner 
There were discrepancies between the answers, for examples the advices received by patients 
and given by dispensers were not consistent. All dispensers 16 (100%) affirmed giving 
advices on side-effects while only 73 patients (34.8%) said receiving this advice.  
In Botswana, a study revealed that 58% of ARV users experienced side-effects (41).  
Dispensers should emphasize on this advice even monitor it though a well organize system of 
pharmaco-vigilance. 
 In Tanzania, patients complained about side-effects of ARV (41) which can limit the 
adherence of HIV causing wastage of the scare resources in poor setting. Several studies have 
found that side-effects can cause non-adherence to treatment. A literature survey  showed that 
19 – 25% of patients quoted side-effects as a cause for non-adherence (44).  
 67
Weiser et al. found that 51% of patients experienced side-effects, and 9% of them considered 
this as a barrier to adherence (21).  
There are similar results from Botswana, 58% and 8% respectively (41). In order to improve 
adherence, Stone  recommends that patients should be informed about possible side-effects 
and how they will be managed (45). 
 Fortunately almost all patients 207 (98.5%) received advice about the directions for use 
(dosage and administration). In Mali, the procurement of ARV is based on tendering system. 
ARV drugs can be found in several dosages, presentations and from different manufacturers. 
In Brazil, changes in packaging of ARVs have been reported as an obstacle to optimal 
treatment (27). The patients get confused and either stop treatment or take their medication 
incorrectly. Poor literacy skills probably add to the confusion. In Botswana, 3% of patients 
reported having misunderstood instructions as a reason for missing medications (41). In this 
case it is very important to have advices on the directions for use. 
5.3.5 Descriptive statistics by site 
Univariate analysis sorted out detailed results by ARV site (HGT, CESAC and HPG) for 
some variables. The following observations were made: 
• HGT had the shortest waiting time and appeared to be the most accessible 
• CESAC had the shortest travel time and distance but the longest waiting time. CESAC 
is less accessible in terms of waiting time at the site. However it was the most 
accessible site financially. 
• HPG had the longest distance, leading to the longest travel time and the highest travel 
cost. Consequently, HPG was the site which was least accessible in terms of distance, 
time and cost of transportation. In addition, the patients who visited this site had the 
highest income. 
The lack of income could constitute a real problem for the accessibility of ARV sites.  
5.3.6 Dependant variables 
Geographical accessibility 
The categorisation for the geographical accessibility by time spent and distance covered 
showed that ARVs were accessible for the majority of the HIV/AIDS patients. 
Financial accessibility 
ARV was accessible for 80 patients out of 87 (92%) who had an income and for whom we 
obtained information on the income value.  
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Opinion of informants about accessibility of ARV 
The majority of HIV/AIDS patients and dispensers felt that ARV was accessible. 
 
Quality of dispensing  
According to the importance of advices received by patients, 114 patients (54.2%) had an 
acceptable quality of dispensing while 69 (32.9%) had a poor quality of dispensing. Only 27 
patients (12.9%) received a good quality of dispensing. This showed that the quality of 
dispensing in terms of advices should be improved by the dispensers. 
 
Patient’s satisfaction with the manner of dispensing 
The majority of the patients 176 (84%) were satisfied with the manner of dispensing. They 
received friendly service at the dispensing site even though the waiting time was the longest 
at CESAC. However, many of them complained about the dispensing manner at CESAC.  
 
Staff coverage for dispensing 
Between May 2005 and July 2006 the number of patients on ART in Bamako increased from 
3 102 to 6 343 more than the double (29). In July 2006 there were 16 ARV dispensers, giving 
a ratio of 396 patients per dispenser. However, the number of dispensers per site did not 
match the number of patients. In CESAC each dispenser had to cope with 1 066 patients, in 
HPG 461 and in HGT only 144 patients. The difference between the sites is reflected in the 
long mean of waiting time in CESAC (two and a half hours), and the patients’ opinion about 
waiting time to get ARV: 74% said that they spent a long time, compared to 19% in HPG and 
7% in HGT. Each dispenser can, in theory, be available for dispensing 1 680 hours per year (7 
hours, 5 days, 48 weeks). 
 
When planning to introduce ART in the public sector in Botswana (46), it was estimated that 
total pharmacist + pharmacy technician time per patient per year would be 0.6 + 2.0 hours. 
Assuming that this estimate is relevant for the situation in Bamako, each dispenser could be 
able to dispense for a total of 646 patients per year. In this case, the dispensers in CESAC are 
already overstretched, whereas there could be some spare capacity in HGT.  
 
Only four of the 16 dispensers available in July 2006 were permanently allocated for 
dispensing, the others were pharmacy students. If the students are not replaced when they 
finish their studies, there will be a dramatic reduction in dispensing capacity. This, combined 
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with the expansion of the ART programme, could endanger the whole ART programme. 
Either more pharmacists must be recruited, or other solutions found to increase dispensing 
capacity.  
A similar situation has been experienced in other countries, e.g. in Tanzania where the 
increase in number of patients lead to heavy work loads for health care staff (41). A shortage 
of health care workers is a general problem in many African countries. Mali has only 1.9 
health care workers for 1000 people (47). 
In order to increase capacity to deliver HIV services, WHO has started to promote so-called 
task-shifting, by moving some tasks from highly qualified health staff to less specialized 
personnel (47). The feasibility in Mali of training other categories of personnel in ARV 
dispensing, could be explored. 
5.3.7 Disclosure challenge 
Stigma and discrimination are two of the greatest barriers to dealing effectively with the HIV 
epidemic. They deter people from finding out about their HIV status, and prevent HIV 
positive people from taking steps to protect others and seeking treatment for themselves.  
In a study in Botswana in 2000, Weiser et al. found that 15% of patients answered that stigma 
was a barrier (21) . In a summary of three country studies, Hardon et al. reported that after 
disclosing their HIV-positive status, some patients had lost their jobs, others were abandoned 
or badly treated by their partners, or were isolated by community members (41). In Botswana, 
27% of patients said that they feared to lose their job because of HIV status (48).  
In this study 6 of the 210 patients (2.9%) answered that they considered stigma as a problem 
that could prevent them from getting ARV. However, some of the patients’ answers to other 
questions indicate that stigma might be a more widespread problem: 
- One patient travelled a much longer distance than necessary to the treatment site, 
presumably to avoid disclosure 
- Four patients had difficulties leaving their jobs to get ARV because they had not disclosed 
their HIV status. 
- There were 20 divorced females among the 210 patients (80% of the divorced patients), 6 of 
them said that they had been abandoned by their husbands 
- Some patients even reported that they have to use other excuses in order to go to the 
treatment site 
In Morocco, more female patients were divorced than male (26).  
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A study from Tanzania showed that the disclosure of HIV status increased support/care from 
family members (49). Another study from South Africa reported that the disclosure of HIV 
status was important for treatment adherence (42). Similarly, Klitzman et al. reported that 
HAART lead to increase in HIV disclosure and support (50). 
5.3.8 Gender analysis 
There was gender difference in terms of income, means of transportation and advice on new 
appointment. The majority of female patients 125 (90.5%) used public means to reach the 
ARV sites while 29 male patients (40.3%) had their own means of transportation 
In Morocco for example the gender did not influence the means of transportation (26). 
However gender did not influence the travel distance, cost of transportation, waiting time, 
frequency of ARV reception, existence of difficulties, satisfaction on dispensing manner, 
advices on ARV and quality of ARV dispensing. This shows equity on ARV access according 
to gender at the treatment site. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
6.1 CONCLUSIONS 
 Cross sectional quantitative study was conducted in Bamako, the capital city of the Republic 
of Mali in the three ARV sites HGT, CESAC and HPG.  
The study included 210 HIV/AIDS patients under ART for at least one month (43 at HGT; 
106 at CESAC; and 61 at HPG) and 16 dispensers (9 at HGT; 3 at CESAC; and 4 at HPG). 
 The sex ratio for patients was 1.9, approximately two female for one male. The mean age for 
patients was 35.17 ± 9.23 years. The majority of the patients 183 (87%) were residing in 
Bamako while only 27 (13%) were coming from outside Bamako.  
According to respondents’ opinion and the dependant variables on geographical (distance 
covered and time spent to reach ARV site) and financial accessibility (percentage income by 
cost of transportation), ARV drugs were accessible for the majority of the HIV/AIDS patients. 
Also the majority of patients were satisfied with the dispensing manner.  
But some difficulties still existed.  The findings of this study enabled observation and 
demonstrated some organisational issues and lapses at the treatment sites such as the long 
waiting time at CESAC for example, compulsory medical check-up even if not necessary. 
This time leads to an additional expense for food and drink.  There were discrepancies 
between the responses of patients and dispensers according to the advices given by dispensers 
and those received by patients. 
The stigma appeared to be a big issue even though it was under-reported by HIV/AIDS 
patients. This could be illustrated by the high number of divorce among female patients or 
those being abandoned by their husbands, the long travel distance and time covered by some 
patients. The difficulty experienced in getting permission from job has also been cited. 
The study showed differences between the three ARV sites and between genders.  
This study enabled identification of the impact of some risk factors which might limit the 
accessibility of ARV even though some were more important than others. Generally, it 
pointed out some logistic, socio-economic, and organisational issue of health staff. These can 
be explored by performing an analytic case control or cohort studies for a better elucidation of 
this public health matter. However another study should permit also to explore the patients 
who still have no access at all to ARV drugs.  
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6.2 RECOMMENDATIONS 
The attainment of the specific objectives as outlined at the beginning of the study, in the three 
ARV sites at Bamako, Mali (HGT, CESAC and HPG) on HIV/AIDS patients and dispensers 
facilitating the following recommendations: 
To the health authorities: 
• A need to provide guidelines for ARV dispensing especially in connection with ways 
of improving communication or advices to HIV/AIDS patients. The guidelines are to 
be issued  by the National High Council for AIDS control  (Haut Conseil National de 
Lutte contre le Sida  HCNLS) 
• A need to organise specific unit for pharmaco-vigilance to monitor the side-effects of 
ARV. This responsibility is directly required from the Direction of Pharmacy and 
Medicines (Direction de la Pharmacie et du Médicament DPM)  
• To establish a motivation plan (incentives: salary, training/education, etc) for the 
health staff 
• To institute a curriculum on ARV dispensing at the pharmacy schools 
• To included the same subject in the curriculum of medical schools  
• To give practical training to students on ARV dispensing and supportive supervision 
• To subsidize transportation cost for HIV/AIDS patients which incur on their journey 
to the treatment site 
• To decentralise the ARV administration or dispensing sites as much as possible like 
TB drugs. This will make the drugs more accessible through the district health centers 
and community health centers. 
• To improve and monitor counselling 
• To encourage research collaborations on AIDS and ARV   
 
To the ARV dispensers: 
• To improve the organisation of dispensing by drawing up realistic appointment 
schedules to reduce the long waiting time. Additionally, to endeavour and integrate or 
engage other health staff in the process such as nurses while ensuring that 
responsibility remains with the pharmacist. 
• To train the non-pharmacists in procedure of making proper dispensing of ARV 
according to the guidelines. 
• To follow the dispensing guidelines for ARV. 
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• To intensify IEC (Information, Education and Communication) on way of caring for 
HIV/AIDS patients. 
• To organise weekly speeches on the side-effects of ARV for the patients and those 
accompanying them. 
• To emphasize on how to deal with the side-effects of ARV 
 
To HIV/AIDS patients: 
• A better ARV adherence and compliance 
• The respect of appointment and advices on ARV drugs 
• The need to disclose HIV/AIDS status, as this will help them to get care and support 
from family or community.  
 
To community and organisations such as PLWHA: 
•  To reduce stigmatization towards the HIV/AIDS patients, by encouraging people to 
disclose their HIV status. 
• A community mobilisation by involving the leaders (opinion and religious), NGO for 
purposes of improving understanding on the use of ARV and respect of appointment 
at the treatment site. 
• To construct eating places or canteens at the ARV sites so as to reduce the nutritional 
risks due to ARV and AIDS as well as reducing the aggregate expenditure for getting 
ARV. 
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LIST OF ANNEXES 
Annex 1:  Questionnaire for patients 
 
Questionnaire number: 
ID number 
Interviewer’s name: 
Interview date: 
Name of ARV site: 
 
A SOCIO-DEMOGRAPHIC DATA 
1 Background on antiretroviral therapy (ART) 
1.1. How long are you involve in ART? (in month)  ----------------- 
1.2. At what rate (rhythm) do you get ARV drugs? 
1. Weekly  2. Monthly  3. Quarterly   4. Other 
If Other specify  ----------------------------------  
2 Sex   1. Male      2. Female 
3   Age  
How old are you? (years)      ------------------- 
4 Level of schooling 
4.1. Have you been to a formal school?   Yes   No 
4.2. If No go to 5 
4.3. If Yes at which year do you drop? 
1. 1-6 years    2. 6-9 years 
3. 10-12 years    4. More than 12 years 
5 Marital status  
Could you please tell me which of the following describe your marital status?  
(Check only one category) 
1. Married  Yes   No 
2. Single  Yes   No 
3. Widowed   Yes   No 
4. Divorced  Yes   No 
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6 Profession 
What is your profession?  
1. Civil servant  2. House wife   3. Trader 
4. Peasant (herds-man, farmer and fisherman)  5. Artisan   
6. Student   7. Unemployed  8. Jobless 
9. Other (specify)       ---------------------------------- 
7 Income 
7.1. Do you have a regular income?   Yes   No  
7.2. If yes, how much do you earn per month? (In FCFA) ------------------------ 
7.3. If no, could you tell me your average income per month? (In FCFA)    --------------  
8 Residence 
7.1 Where are you from?      --------------------------- 
7.2 Where do you live?  1= Bamako    2= outside Bamako 
If the person lives in Bamako please specify the area “quartier”   ------------------------- 
 9 Living condition 
9.1 Do you have the following items at home? 
1 Radio          Yes   No 
2 TV           Yes   No 
3 Bike           Yes   No 
4 Motorbike           Yes   No 
5 Car           Yes   No 
6 Refrigerator/Freezer         Yes   No 
7 Other (specify)  --------------------------------------------------------- 
9.2 Do you have your own house?                      Yes   No 
If yes which type of house?   1 Concrete     2   Mud    
3   Other (specify)    --------------------------------- 
If no in which type of house do you live? 
1 Concrete     2   Mud    
3   Other (specify)    --------------------------------- 
9.3 Do you have access to tap water in household?      Yes   No 
9.4 Do you have access to electricity in household?      Yes   No 
9.10 Could you tell me please what kind of toilet you have in household? 
1   Traditional toilet  2   latrine   2   Modern toilet (running water) 
3 Other (specify)  --------------------------------------------------------- 
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B BARRIER DATA 
1 Distance covered 
1.1 Do you think you live far from the ARV site?  
1 Yes   2 No   3 Don’t known 
1.2  What is the distance to reach ARV site (by kilometer) ---------------------- 
2 Time spent 
2.1 Time to reach ARV site 
2.1.1 Do you think you spend much time to reach ARV site?   
1 Yes   2 No   3 Don’t known 
2.1.2   How much time do you spend to reach ARV site (By minute)    ---------------------- 
2.2 Waiting time 
2.2.1 When you reach ARV site, do you think you spend much time to get ARV drugs?   
1 Yes   2 No   3 Don’t known 
2.2.2 How much time do you spend to get ARV drug?  (By minute) ------------------ 
3 Type of transport 
3.1. Do you have your own means of transportation? 
1 Yes       2   No 
3.1.1 If yes, which type?    -------------------------- 
3.1.2 If no, how do you reach ARV site? 
1. By foot   2. Bus    3. Taxi   4. Car  
5. Bike    6. Motorbike              7. Other 
If other specify       ---------------------------------  
4 Cost of transportation 
4.1   If using your own transport means, how much does it cost you to reach the treatment 
site? (In FCFA)   ------------------------------ 
4.2   If using public transport how much does it cost for you to reach ARV site? (In FCFA) 
 
5 Transportation fee 
5.1 Could you please tell me who is paying for your transportation cost? 
1 Yes        2 No  
5.2 If Yes who?    1. Myself   2. Husband/Wife 
 3.Sister/Brother                    4. Friend    5. Other  
 If other specify  ----------------------------------     
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6 Additional cost  
6.1. Do you spend money for anything else except transport cost while waiting for ARV 
drugs (food, water etc)? 
1 Yes        2  No     
If No go to 7 
6.2. If yes, are you spend money on what?   --------------------- 
6.3. How much do you spend? (In FCFA)   --------------------- 
7    Other barriers 
Do you think that there is any other barrier (problem) that prevents you to get ARV drug? 
1 Yes        2  No     
If No go to C 
If yes do you have barrier relative to:   
1 Family 
2 Stigma 
3 Nutrition 
4 Heath center 
5 Other (specify)  --------------------------------------------------- 
 
C OPINIONS ABOUT ARV DRUGS ACCESSIBILITY  
1 Do you think that ARV drugs are accessible?  
1 Yes   2 No   3 Don’t known 
If no, why?   ----------------------------------------- 
If yes, please could you tell me how accessible the drugs are in your opinion? 
1. Very accessible 
2. Accessible 
3. Less accessible 
If less accessible what are your suggestion for better access to ARV drug? 
   ----------------------------------------------- 
    ------------------------------------------------          
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D DISPENSING MANNER 
1 Confidentiality 
Have you received your drugs in presence of other people? 
1 Yes      2 No    
If No go to 2 
If yes, who are these people   --------------------------------------------------- 
How many they are?       ------------------------ 
  2 Advices 
Do you receive advices when you get drugs? 
1 Yes        2  No     
If No go to E 
 
If Yes what kind of advices? 
1 Directions for use (dosage and administration)   Yes    No 
2 Side-effects           Yes   No 
3 Storage           Yes   No 
4 New appointment           Yes   No 
5 Other (specify)  --------------------------------------------------------- 
 
E SATISFACTION ABOUT DISPENSING  
1. Tell me your opinion for the following statement about dispensing manner? 
1 Very satisfied 
2 Satisfied 
3 Not satisfied 
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Annex 2:  Questionnaire for dispensers  
 
Questionnaire number: 
 
Interviewer’s name: 
 
Interview date: 
 
Name of ARV site: 
 
ID number: 
Staff assigned for dispensing (only to site manager): 
Staff doing dispensing (only to site manager): 
Do you have a specific training for dispensing?  1 Yes  2 No 
At what rate (rhythm) do you give ARV 1. Weekly  2. Monthly   
3. Quarterly   4. Other (specify) ----------------------------------  
A SOCIO-DEMOGRAPHIC DATA 
  
1 Sex   1.Male    2. Female 
 
2   Age  
How old are you (years)  ----------------------------- 
 
3 Qualification  of dispenser  
1. Pharmacist  2. Medical doctor          3. Nurse    4.Midwife   5.Other 
If other specify -------------------------------------------   
4 Experience in dispensing 
How long are you involve in ARV drugs dispensing? (In month) --------------------- 
 
B TRAINING 
1   Did you receive training for ARV drugs dispensing? 
1 Yes     2 No    
If Yes which kind of training? --------------------------------------- 
 
2   How many times did you receive training?   ---------------------------- 
 
3   How long was it?  -------------------------------------------------- 
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C OPINIONS ABOUT ARV DRUGS ACCESSIBILITY  
1 Do you think that ARV drugs are accessible?  
1 Yes   2 No   3 Don’t known 
If  no why?   ----------------------------------------- 
 
If yes, please could you tell me how accessible the drugs are in your opinion? 
1. Very accessible 
2. Accessible 
3. Less accessible 
If less accessible what are your suggestion for better access to ARV drug? 
   ----------------------------------------------- 
    ------------------------------------------------  
 
D DISPENSING MANNER 
1 Confidentiality 
Do you give drugs in presence of other people? 
1 Yes     2 No    
If no, go to 2 
If yes, who are these people   --------------------------------------------------- 
How many they are?       ------------------------ 
  2 Advices 
Do you give advices when you give drugs? 
1 Yes     2 No    
If Yes what kind of advices? 
1 Directions for use (dosage and administration)   Yes   No 
2 Side-effects           Yes   No 
3 Storage           Yes   No 
4 New appointment           Yes   No 
5 Other (specify)  --------------------------------------------------------- 
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Annex 3:  Questionnaire for patients (in French) 
 
ACCESSIBILITE DES MEDICAMENTS ANTIRETROVIRAUX AUX  MALADES 
DU VIH/SIDA A BAMAKO, MALI   (Afrique de l’Ouest) 
 
Questionnaire pour le patient 
 
Numéro questionnaire : ……………………………………………………………. 
Numéro d’identification : ……………………………………………………………. 
Nom de l’interviewer : ……………………………………………………………. 
Date de l’interview :   …………………………………………………………… 
Nom du site ARV :  ……………………………………………………………. 
 
A DONNEES SOCIO-DEMOGRAPHIQUES 
1. Généralités sur le traitement antirétroviral  
1.1. Depuis combien de temps êtes-vous sous ARV? (en mois) (E ye waati joli kε  furaba 
taalila? (a kalo hake)…………………………………………………….……………………… 
1.2. A quel rythme recevez-vous les médicaments ARV? (Furaba be d’e ma cogodi?) 
1. Hebdomadaire (Lɔkɔkun ni lɔkɔkun) ; 2. Mensuel (Kalo ni kalo) ; 3. Trimestriel (kalo saba o kalo 
saba?) ; 4. Autre (cogowεrε), spécifier ……………………………………………………….  
2. Sexe   1. Masculin      2. Féminin 
3   Age : Quel âge avez-vous? (années) (N’Fa/N’Ba, Ala ye si sanjoli kalifa i la?)…………… 
4 Niveau d’instruction  
4.1. Avez-vous été à l’école : (I kalan na wa?) 
     Francophone    Oui   Non 
          Medersa    Oui   Non 
          Autres (préciser) : ………………………………………… 
4.2. Si Non, aller à la question 5 
 
4.3. Si Oui, à quel niveau vous avez arrêté (I ka kalan dan na hake joli la)? 
1. Ecole primaire (1 – 6 ans);  2. Second cycle (7 – 9 ans)   
3. Niveau secondaire (Lycée, CAP, BT) ;  4. Supérieur  
 
4.4.  Savez-vous lire (I be se ka seben kalan wa) ?  Oui  Non 
 86
4.5.  Savez-vous écrire (I be se ka sεbenni kε wa) ?  Oui  Non 
5. Statut matrimonial  
S’il vous plaît, pouvez-vous me dire votre statut matrimonial (Hakεto, i furelen do wa / N’Fa/N’ba 
walima, i be haketo an b’a/f’a  be so yan wa ? 
(Cocher seulement une catégorie)  
1. Marié (e)  Oui   Non 
2. Célibataire   Oui   Non 
3. Veuf (ve)   Oui   Non 
4. Divorcé (e)  Oui   Non 
5. Autre (préciser) : …………………………….. 
6. Profession 
Quelle est votre profession (I be bara jumε na / kε) ?  
1. Salarié (Kalosara bara) : spécifier ……………………………..  
2. Ménagère (gwa/tobili) ;  
3. Commerçant (jagokεla/jula) ;     
4. Paysan (éleveur = bagankεla, cultivateur = cikεla et pêcheur = monikεla / bozo) ; 
5. Artisan (bololabarakεla) ;  
6. Etudiant (Ekolidenkunbaba/Kalansobakalanden) ;  
7. Sans emploi (barakεbali) ; 8. Vendeur (ferelikεla) ; 
9. Autre (spécifier) :……………………………………………….. 
7. Revenu 
7.1. Avez-vous une source de revenu (Wari soro da b’ibolo wa) ?  Oui  Non 
7.2. Si Oui, combien gagnez-vous approximativement par mois? (en FCFA) (Ni awɔ, i ka 
sɔrɔ be se jolima tilenkɔnɔ walima kalokɔnɔ) ……………………………………………………………. 
7.3. Si Non, comment arrivez-vous à subvenir à vos besoins de base (ni ayi, e b’i ka musaka 
sɔrɔ cogodi/E be jɔ ni ka musakaw ye cogodi) ? 
1.  Famille (Mansaw/Balimaw) ; 2. Association (Dεmεjεkunlu/Tɔn)  ;  
3. Entre-aide (Dεmεbolo/Dεmεbolosira) ; 4. Autre (préciser) : ………………………………… 
8. Résidence (sigiyɔrɔ/dagayɔrɔ) 
7.1 De quelle région ou pays venez-vous (I be bɔ min / I be bɔ dugujumε ŋa) ? …………………. 
7.2 Où habitez-vous actuellement (I sigilen bε mi sissan) ? 
1= Bamako ; 2= en dehors de Bamako (spécifier) :………………………………………….. 
Si la personne vit à Bamako veuillez spécifier le quartier:…………………………………… 
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 9. Conditions de vie 
9.1 Avez-vous les matériels suivants à la maison (Ni fin ninuw b’i bolo so wa) ? 
1 Radio          Oui   Non 
2 Télévision          Oui   Non 
3 Vélo           Oui   Non 
4 Moto            Oui   Non 
5 Voiture          Oui   Non 
6 Frigo/Congélateur         Oui   Non  
7 Autre (spécifier) :………………………………………………………………….. 
9.2 Avez-vous votre propre maison (I yεrε halalaso b’i bolo/b’i fε wa) ? Oui  Non  
Si Oui, quel type de maison (so sugu jumε)?  1.Ciment/parpain ; 2. Ciment/béton ; 3.  Banco 
4   Autre (spécifier) :…………………………………………………………………….. 
Si Non, où vivez-vous ? (I be so jumε kɔnɔ?) 
1.   Location   2.   Concession familiale  3.   Maison de service  
4. Autre (spécifier) ………………………….……………………………... 
Dans quel type de maison vivez-vous ? (I be si so sugu jumε kɔnɔ?)    
1. Ciment/parpain ; 2. Ciment/béton ; 3.  Banco ; 4.Autre (spécifier) :……………………… 
9.3 Avez-vous de l’eau courante à la maison (Orobinε b’aw ka dukɔnɔ wa) ?  Oui Non 
9.4 Avez-vous l’électricité à la maison (Kuran be du kɔnɔ wa) ?         Oui Non 
9.5 Pouvez-vous me dire quel genre de toilette vous avez à la maison (i be haketo ɲεgen sugu 
jumε b’a ka so)?  
1. Toilette traditionnelle (farafinɲεgen) ; 2. Latrine (latirini) ; 3.Toilette moderne (chasse-
eau : tubabuɲεgen) ; 4. Autre (spécifier) :…………………………………………………………. 
 
B DONNEES CONCERNANT LES BARRIERES 
1. Distance couverte 
1.1 Pensez-vous que vous êtes éloigné du site ARV (I hakilila k’i ka yɔrɔ ka jan furaba tayɔrɔ la 
wa) ? 1. Oui   2. Non   3. Ne Sait Pas  
1.2  Quelle est la distance pour arriver au site ARV (par kilomètre) (I ka yɔrɔ ni furaba tayɔrɔ 
cε be kilohake joli bɔ) ?............................................................................. 
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2. Temps mis 
2.1 Temps pour arriver au site ARV  
2.1.1 Pensez-vous que vous prenez beaucoup de temps pour arriver au site ARV (Yali i be waati 
cama ta i ka yɔrɔ ni furaba ta yɔrɔ cε wa) ?  1. Oui ; 2. Non ; 3. Ne Sait Pas  
2.1.2   Combien de temps faites-vous pour arriver au site ARV (par minute) (I be waati joli kε i ka 
yɔrɔ ni furaba ta yɔrɔ cε) ? …………………………………………………………….. 
2.2 Temps d’attente 
2.2.1  Quand vous arrivez au site ARV, pensez-vous que vous restez longtemps avant de 
recevoir les médicaments ARV (E bolo, I be mε k’i ka furaba makɔnɔ wa ) ?   
1. Oui  ; 2. Non ; 3. Ne Sait Pas 
2.2.2 Combien de temps faites-vous pour recevoir les médicaments ARV (par minute) (waati 
joli be tεmε ka sɔrɔ i m’i ka furaba sɔrɔ) ? 
2.2. 3 Combien de temps faites-vous pour recevoir l’ordonnance (par mn)  (I be waati joli kε 
soni i  ka furabasεben sɔrɔ) ? ………………………………………………………………………………………………………….   
3 Type de transport 
3.1. Avez-vous votre propre moyen de déplacement (I yεrε ka bolifin b’i bolo wa)? 1.Oui ; 2.Non 
3.1.1. Si Oui, quel type (Ni, awɔ, bolifin sugun jumε) ?................................................................ 
3.1.2 Si Non, comment venez-vous au site ARV (Ni ayi, e be ta cogodi furaba tayɔrɔ la) ?  
1. à pied   2. Bus    3. Taxi   4. Voiture  
5. Vélo  6. Mobylette            7. Minicar (Sotrama)  8.  Autre 
Si Autre specifier    ---------------------------------  
4 Prix du transport 
4.1   Si vous utilisez votre propre moyen de transport, combien cela vous coûte t-il pour  
arriver au site de traitement (N’i bina I yεrε ka bolifin na, o musaka be ben joli ma) ? (en FCFA)……… 
4.2   Si vous utilisez les transports publiques, combien cela vous coûte t-il pour arriver au site 
de traitement (N’i bina foroba bolifin ŋ furaba ta yòrò la, o musaka be ben joli ma) ? (en FCFA)………….. 
5 Frais de transport 
5.1 Pouvez-vous me dire qui paye vos frais de transport (I be se ka fɔ n’ye min b’i ka pase sara 
wa/Jɔnni b’e pase sara) ?   1 Oui   2 Non  
5.2 Si Oui, qui ?   1. Moi-même ; 2. Epoux ; 3. Epouse ; 4. Frère ; 5.Soeur ; 6. Amis
         7. Autre (spécifier) :…………………………………   
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6 Coût additionel  
6.1. Dépensez-vous de l’argent en dehors du prix du transport pendant que vous attendez 
de recevoir vos médicaments ARV (nourriture, eau, etc) (I be waari wèrè bò i mago la furaba 
makònò ni na, n’i ba fô dumuni, ji walima fin wèrè sanni na wa)?  1.Oui ; 2. Non   
Si Non, aller à la question 7. 
6.2. Si Oui, qu’est- ce que vous achetez (I be mun ni mun san) ?................................... 
6.3. Combien dépensez-vous (I ka waari bôlε be se fô joli ma) ? (en FCFA)………………. 
7. Autres barrières 
Pensez-vous qu’une autre chose ou problème peut vous empêcher d’avoir les médicaments 
ARV ( I hakila ko fin wèrè be se ka gèlèya do i ka furaba sôrôli la wa) ? 1.Oui ; 2. Non   
 
Si Non, aller à la rubrique C des questions 
Si Oui, avez-vous une barrière relative à (ni awô, yali balanyôrô bè wa):   
1 Famille (I somôgôw fanfèn wa ?)  
2 Stigma (stigmatisation = bolokôni yiralin fanfèn wa ?) 
3 Nutrition (alimentation = duminidèsè walima dumunigèlèya fanfèn wa ?) 
4 Center de santé (dôgôtôrôso yèrè taali la wa ?) 
5 Personnel de santé (dôgôtôrôso barakèlaw fanfèn wa ?) 
6 Autre (spécifier) :……………………………………………….. 
 
C. OPINION SUR L’ACCESSIBILITE DES MEDICAMENTS ARV 
1 Pensez-vous que les médicaments ARV sont accessibles (I hakilila ko furaba lasôrôli 
ka nôgô wa) ? 1. Oui ; 2. Non ; 3. Ne Sait Pas 
Si  Non, pourquoi (ni ayi, munna) ?   ----------------------------------------- 
Si Oui, pouvez-vous me dire votre opinion sur le degré d’accessibilité des médicaments ARV 
(Ni awô, i be se k’i ka hakilina/ta jôn-jôn fô n’ye furaba lasôrôli kan wa) ? 
1. Très accessibles (sôrôka diya !) 
2. Accessibles (sôrôka nôgôn !) 
3. Peu accessibles (sôrôka gèlèma/sôrôli gèlèya !) 
 
Si peu ou pas accessibles, quelle est votre suggestion pour un meilleur accès aux médicaments 
ARV (N’a sôrôli ma nôgô/ka gèlèn walima na te sôrô yèrè, fèrè jumè be se ka tigè min b’a tò, 
a sôrô be diya aw fè !) ?..................................................  
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D. MANIERE DE DISPENSER  
1. Confidentialité 
Avez-vous reçu vos médicaments ARV en présence d’autres personnes (I ka furaba be deli ka 
d’i ma jama yana wa) ?  1. Oui  2.  Non    
Si Non, aller à la question 2. 
Si Oui, qui sont-elles  (Ni awô, môgô jumèw ?) ? : …………………………………………… 
Combien sont-elles ? (Môgô joli) ? :………………………………………………………….. 
Que pensez-vous de leur présence (E hakilina ye jumèw ye (i ka furaba dili ye o môgôw 
nyana)? : 
………………………………………………………………………………………..…………. 
  2. Conseils 
Recevez-vous des conseils quand on vous donne vos médicaments ARV (Yali, kunnafoni be 
d’i ma i ka furaba di tô wa) ?   1. Oui   2.  Non   
  
Si Non, aller à la rubrique E des questions. 
Si Oui, quel genre de conseils (Ni awô, o ye kunnafoni jumèw ye) ? 
1.  Dosage et mode d’administration (furaba denhake n’a ta cogo)   Oui Non 
2. Effets secondaires (furaba tali bese ka dengun walima tôrô min se i ma)   Oui Non 
3. Conservation (furaba lasago cogo nyuma)     Oui Non 
4. Rendez-vous (A ka nyôgôn kunnafoni / Arandevu)     Oui Non 
5. Autre (spécifier) (Kunnafoni wèrè) : ………………………………………………….. 
 
E SATISFACTION PAR RAPPORT A LA DISPENSING  
 Pouvez-vous me dire votre opinion sur la manière de dispenser (I be k’i 
hakilinata/miiriya fô n’ye furaba di cogo kan wa) ? 
1 Très satisfait (I wasalen kosebè !) 
2 Satisfait (I wasalen !) 
3 Non satisfait (I ma wasa !) 
4 Pas du tout satisfait (I ma wasa fiyeu !) 
 
 
I nin ce a kè dèmè ni ka timinandiya la (Je vous remercie de votre participation et patience) ! 
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Annex 4:  Questionnaire for dispensers (in French) 
 
ACCESSIBILITE DES MEDICAMENTS ANTIRETROVIRAUX AUX  MALADES 
DU VIH/SIDA A BAMAKO, MALI   (Afrique de l’Ouest) 
 
  Questionnaire pour  le dispensateur  
 
Numero questionnaire : ---------------------------------- 
Nom de l’interviewer: ---------------------------------- 
Date de l’interview:  ---------------------------------- 
Nom du site ARV:  ---------------------------------- 
Numéro d’identification: ---------------------------------- 
 
Staff assigné pour la dispensing (seulement au gestionnaire du site): -------------------- 
Staff faisant la dispensing (seulement au gestionnaire du site ):  -------------------- 
A quel rythme donnez-vous les ARV ?  
1. Hebdomadaire  2. Mensuel  3. Trimestriel   4. Autre 
Si Autre, spécifier  ----------------------------------  
  
A DONNEES SOCIO-DEMOGRAPHIQUES 
1 Sexe   1.Masculin    2. Féminin 
 
2   Age  
Quel âge avez-vous? (années)      ------------------- 
3 Qualification du dispensateur 
1. Pharmacien  2. Médecin          3. Infirmier  4. Sage-femme   5.Autre 
Si autre, spécifier -------------------------------------------   
4 Expérience en dispensing 
Depuis combien de temps dispensez-vous les médicaments ARV? (en mois)  ------------------- 
 
B FORMATION 
1   Avez-vous reçu une formation pour la dispensing des médicaments ARV? 
1 Oui     2 Non    
Si Oui, quel genre de formation?   --------------------------------------- 
2   Combien de fois avez-vous reçu une formation?   ---------------------------- 
3   Durée de la ou des formation (s)?  -------------------------------------------------- 
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C. OPINION SUR L’ACCESSIBILITE DES MEDICAMENTS ARV 
1 Pensez-vous que les médicaments ARV sont accessibles?  
1 Oui   2 Non   3 Ne Sait Pas 
Si  Non, pourquoi?   ----------------------------------------- 
Si Oui, pouvez-vous me dire votre opinion sur l’accessibilité des médicaments ARV? 
1. Très accessibles 
2. Accessibles 
3. Peu accessibles 
Si peu ou pas accessibles quel est votre suggestion pour un meilleur accès aux médicaments 
ARV? 
  ------------------------------------------------ 
  ------------------------------------------------  
 ------------------------------------------------- 
 
D MANIERE DE DISPENSER  
1 Confidentialité 
Donnez-vous les médicaments ARV en présence d’autres personnes? 
1 Oui      2 Non    
Si Non, aller à 2 
Si Oui, qui sont-elles   --------------------------------------------------- 
Combien sont-elles?     ------------------------ 
  2 Conseils 
Donnez-vous des conseils quand vous donnez les médicaments ARV? 
1 Oui        2  Non     
Si Non, fin de l’interview 
Si Oui, quel genre de conseils? 
1 Dosage et mode d’administration       Oui    Non 
2 Effets secondaires          Oui   Non 
3 Conservation           Oui   Non 
4 Rendez-vous            Oui   Non 
5 Autre (spécifier)  --------------------------------------------------------- 
 
 93
Annex 5:  Consent form for patients (in French) 
 
Formulaire de consentement volontaire éclairé / Patient  
 
Salutations d’usage : 
Je suis .................................................... de.................................................... 
Nous aimerions vous demander de prendre part à notre projet de recherche.  
 
1. But de l’étude :  
Le but de l’étude est de voir en quoi, le fait de la gratuité des médicaments ARV, les 
personnes vivant avec le VIH ou malades du SIDA sont confrontés pour l’accessibilité aux 
ARV. 
 
2. Objectif général  
Identifier les barrières potentielles de l'accessibilité des médicaments ARV aux malades du 
VIH/SIDA. 
 
3. Mode de recrutement du participant : 
La personne vivant avec le VIH ou malade du SIDA sera recrutée en fonction de l’ordre de 
dispensing des médicaments ARV au niveau du site d’étude. Toute personne vivant avec le 
VIH ou malade du SIDA disposée à participer à l’étude après avoir reçu son médicament sera 
interviewée (malade qui fera partie des critères d’inclusion). Le choix du lieu de l’interview 
relevant des convenances du sujet participant à l’étude. 
 
4. Avantages/Bénéfices :  
Il n’y a pas d’avantages directs pour votre participation, mais les résultats de notre recherche 
pourraient aider les décideurs à améliorer l’accessibilité des médicaments ARV aux personnes 
vivant avec le VIH et aux malades du SIDA. Une compensation en terme de frais de transport 
ou de rafraichissement sera offerte au malade. Elle s’élève à 1 500 FCFA. 
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5. Risques possibles encourus :  
La participation à cette étude est volontaire. Le risque encouru pourrait être le non respect de 
la liberté, dignité ou/et du droit du participant en matière d’intimité, d’anonymat ou de 
confidentialité. A cet effet, nous donnons l’assurance au sujet participant qu’à aucun moment, 
son nom n’apparaîtra ni sur le questionnaire ni dans les rapports, publications ou tout autre 
document issu de cette étude. 
 
Chaque participant aura un numéro d’identification en fonction du site ARV. Tous les 
renseignements fournis par l’informateur resteront anonymes et confidentiels. A tout moment 
le participant peut se retirer de l’étude sans aucun préjudice.  
L’acceptation ou le refus de participer n’affectera en rien les relations ou/et les soins que vous 
obtiendrez ici au site du traitement. 
 
Vous êtes libre de nous poser des questions que vous désirez et de prendre contact avec notre 
principal responsable, superviseur local de nos études de terrain, le Dr Cisse Hamma. 
Cellulaire : 00 223 675 23 52 ; Email : h2cisse@yahoo.fr/hama.cisse@sdc.net. 
Vous pouvez également, à tout moment, prendre contact avec le président ou le secrétaire 
permanent du comité d’éthique de la Faculté de médecine, de pharmacie et d’odonto-
stomatologie (FMPOS), Université de Bamako au 00 223 222 52 77  
Fax : 00 223 222 96 58. 
Etes-vous d’accord pour participer à cette étude?    1. Oui       ;          2. Non 
 
Si oui, êtes-vous d’accord pour le consentement verbal ou signé?   
      1. Verbal ; 2.  Signé 
Signature de l’interviewer.......................................................... 
 
Signature du participant ou empreinte digitale ............................... 
 
Signature du témoin ou empreinte digitale.................................. 
 
Code du participant. : /...../...../...../...../...../....../...../...../ ; Date : /........./......./.........../ 
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Annex 6:  Consent form for dispensers (in French) 
 
Formulaire de consentement volontaire éclairé / Dispensateur 
 
Salutations d’usage : 
Je suis .................................................... de.................................................... 
Nous aimerions vous demander de prendre part à notre projet de recherche.  
 
1. But de l’étude :  
Le but de l’étude est de voir en quoi, le fait de la gratuité des médicaments ARV, les 
personnes vivant avec le VIH ou malades du SIDA sont confrontés pour l’accessibilité aux 
ARV. 
 
2. Objectif général  
Identifier les barrières potentielles de l'accessibilité des médicaments ARV aux malades du 
VIH/SIDA. 
 
3. Mode de recrutement du participant : 
Tous les dispensateurs des 3 sites ARV de Bamako seront recrutés. Tout dispensateur disposé 
à participer à l’étude sera interviewé. Le choix du lieu de l’interview relevant des 
convenances du sujet participant à l’étude.  
 
4. Avantages/Bénéfices :  
Il n’y a pas d’avantages directs pour votre participation, mais les résultats de notre recherche 
pourraient aider les décideurs à améliorer l’accessibilité des médicaments ARV aux personnes 
vivant avec le VIH et aux malades du SIDA. Une compensation en terme de frais de transport 
ou de rafraichissement sera offerte au participant. Elle s’élève à 1 500 FCFA. 
 
5. Risques encourus :  
La participation à cette étude est volontaire. Le risque encouru pourrait être le non respect de 
la liberté, dignité ou/et du droit du participant en matière d’intimité, d’anonymat ou de 
confidentialité.  
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A cet effet, nous donnons l’assurance au sujet participant qu’à aucun moment, son nom 
n’apparaîtra ni sur le questionnaire ni dans les rapports, publications ou tout autre document 
issu de cette étude. 
 
Chaque participant aura un numéro d’identification en fonction du site ARV. Tous les 
renseignements fournis par l’informateur resteront anonymes et confidentiels. A tout moment 
le participant peut se retirer de l’étude sans aucun préjudice.  
L’acceptation ou le refus de participer ne vous causera aucune répercussion négative. 
 
Vous êtes libre de nous poser des questions que vous désirez et de prendre contact avec notre 
principal responsable, superviseur local de nos études de terrain, le Dr Cisse Hamma. 
Cellulaire : 00 223 675 23 52 ; Email : h2cisse@yahoo.fr/hama.cisse@sdc.net. 
Vous pouvez également, à tout moment, prendre contact avec le président ou le secrétaire 
permanent du comité d’éthique de la Faculté de médecine, de pharmacie et d’odonto-
stomatologie (FMPOS), Université de Bamako au 00 223 222 52 77  
Fax : 00 223 222 96 58. 
Etes-vous d’accord pour participer à cette étude?    1. Oui       ;          2. Non 
 
Si oui, êtes-vous d’accord pour le consentement verbal ou signé?   
      1. Verbal ; 2.  Signé 
 
Signature de l’interviewer.......................................................... 
 
Signature du dispensateur........................................................... 
 
Code du participant. : /...../...../...../...../...../....../...../...../ ; Date : /........./......./.........../ 
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Annex 7:  Ethical approval from Norway 
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Annex 8:  Ethical approval from Mali 
 
